%PDF-1.6 % 42 0 obj <> endobj 62 0 obj <>/Filter/FlateDecode/ID[<0DC88616E7EFC848A53E432565F5C6CA><33D73130D12D3D42A986E5D8F7DEAAFF>]/Index[42 33]/Info 41 0 R/Length 94/Prev 172196/Root 43 0 R/Size 75/Type/XRef/W[1 2 1]>>stream hbbd``b`$CAD3Hpl@ }bVq$R<usH Ě b ma`bd d100Fg< 6 endstream endobj startxref 0 %%EOF 74 0 obj <>stream hb```e``rc`a`X]π L@9+ {O\AeIGH 0H'PÔaepIpErF/ v5 ]@|n0o0T-@ endstream endobj 43 0 obj <> endobj 44 0 obj <>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 45 0 obj <>stream hެMK@PvP MkIZh !mƸVɦ*A}gxIDD>ADD}˜A'@1) ld6,xs6eNiB6&~NwuRSYb@peV!KeJu:/f܌TQ"pv!X>v} ]t㢫]ίjdmun`C% 5_gΐL=h*796dFEV)[`!mv'\-u]bNOl>ܘڶxԧ-hQ"6g7J;vFD {^_+IE[aVnϕT#e~l}s%+42GQ/e/Xo\u) ?/|C&k1 endstream endobj 46 0 obj <>stream HW[oW~Gs )$PT/UU{vwugw@ \<|3iF ~"* iJ6nvV٧#K+>?J?CH%-%\RAq"G1=h{n\@1T8'ķ=`XA!E /DO;._->JT41:R'*%^-v'/O'h&I+Md:j^;| +_'Z S-jΠ sFY|h @Px/CfYE ˻zu?i@M5%@n &x^&$K.Ϙ}sx`28$ѱ7JPC t;s58Wmwl6$AD_sQ{Ǧa5͡$ƛw%p&qqkЫM]wD‹rN` (,F=vXsmL^ "LJї)d6&Y>4x9`)IR=3`K\'9 xd!~?868 ߡoh*Z1QsL9T 9(`*Jō喕P](TcM7M$yIBW~ߠ&"B}2#2 v/%!př;'vx_IiN [ɰh1'rAAE~ $ \j,<Ju s]HiRXV;&۳%LH~ D,b\؎C3 QP-F}Uh{ආ 8qS!H {&#Jx$ðoYfu89{,EX]/>ƍl&r{1eHOsV]%s4gKG~`Zg2f{{s #^xv\J~]WQMAqC+XM!PC)nO >)^L;g~ #F;3S̅@/>iՑr0l7#MW*v/OOâ,)*M~^-],9oB(0͹ө,:cܿ&hikrhNBYaL-: 6_C.3h:ApT=} ҜqRw0sWL@GrL%Sĵo8zTFI[OnәԉI&r /~Li8>^鲛=l~1Ef9ǔ_q()~U'Ps,x} -j2&4p|M =C"yX&tRL+0c' QR+ۤwwF/ϓ='rC3<`%V>޼N$yunN2Ys4Z{. Y ho(Q6{?]u0o?p;{)HiRF',_S&QTO8,J«bu= endstream endobj 47 0 obj <>stream HWKo8WhXrC{Z -M@H$%R]hh8뛙PsCͮ0u?9P"m!'ZǛ[pK^On7f"/nn>nn}9?x:ȇT PηOQ;%$bB#Rra=W_C0LEj@AGc{Æxw3 e1.=CYg,ȷDlz˨J d kłX{ Q(nH'ˈ00*;>); NF]IF!$0]{kq46Yl4t\eU+"EДY 嵫t/!j- $*6DW%Q jO!ZBrL @D3+zD%b%S riNU }|Z-ۇX ϯdQ& )r<\ ն5cبe EH3jc}P=&sѕa!pIDH̢yO ~ڿ}9"qڴ2h˗uLN 9W.bljSnDz E"x9,@ }ђb.hV.yޞ|oFΧj- 8Vةt|>NsbFn$IwU~&,a;‰TIC#_j#Dx aMIrla١ջurA$pTI烖(_T}8uP fgC/Udpb32 zׁ`Y?Ӛ0xZ⇽0ޚ .Ǘ?vmk2pJ 0QVe< _j_ƸWodg9xmN (6S ̸KHҁߎj,d6?1v `-0@]ӗ@Z4z/C^LŦK?nIrɏMz_{O&nVkNNy=g= C7tĦHA'&^.sf\HSjV3l QYژAC2zE&A*U~8yjL2|+`Z,&:BG:~Z7/s:1z]RkP{C\E x:p '/ %I-AA:/gSCZLg̅[Xzݒ(6rm[-)t8L>1L5c&}+%/+#utda-8?粬VH+ZIbeZ HW3_M\͚g(h`'{z9BϢo0'W߂OM]՗jWe' +uσwAsV.-+RdX.I(׸ğ5'w$ -vɁ|C\A34$X(jɏ}3W # endstream endobj 48 0 obj <>stream HWn6+tf~IS"3*l){EJ)'F#yXcTE%n*$}ҵp/_p}c67wPjlhneͿ>{fqGv#L*-NVBԘU[Q5s+ڮm@`AکG~7ф]^3,Rˌi^0~IPqjbx(#& >A㚨6rz?/xJIƔ$*Nz0ΉpS/{Sp .xr# mzZ)h-iп9T3;`"'.\:iIK:`trl1scƤBrNYmwzb+gf pڶ=ڊ8lTOx=j~c#O8 f\*Xl.J.%'.m׍'9#_X]&JK9Y ~WAaN힗=hDDJ+IhB*e,"p.($Q RJ"w]ۅJgc}G96IBݍe{~es;95kh=6fol'e_ȁDr87߬l*Qq/x~6+W%n{&>stream HWn}W0o3N 36CRHi }6Iwv!WWWթ:uJ0'pKլJcצx},>wpɋÇ8tIRBS w1;ʘv.(ܢ]ta7]uF/ׅB S245)LXȄ\1bD!%FNyy}zs<l)e|u_ձ=C%}ݱ<5/T?KS]~hϟ B945Z-V?*Ľ0-3xmGe _VnlںyjUvn PS#xb vU\M=k6B>5Us  *"X͹6XΥ387S7"8qh`*vCaY@)8W`)$Al0ʔ Tf˚;Ă$TO5D8N䭸:jCOnP(,}RLށ1"3:V{d%RW_y7<#.}3-}$V318~w&<\nǻO!'vųB@YB u[umXI8%}SSPlj8VlduxĐ5u 'J>x5 ,l$[,gHr]L˻U9cGRA,\++`+f /h;' kvkSsc9]^X9O^Dk4\[O(Ճ ?gE -z};a]n0NZrI3[-^Z7HSpPGXF,跌.IyeX<7fԦsfSpSK@B%&#C^Kfܤ&:fv܅՚ 7iӠ׷3 ^Ј#ظ$[3l/UyAW锓^%k]bKsSqUsJH;E_4]J\\pѱu׌]4hDjKOx c\)ypL=?@$Kɿ!{v*)H(!BZEVM(e؈:ns?,DN.̯9-9 VַG (k}oma6eJf336p[p(dO(ˤ8 ekSB+_tGԃw=,2ijh%+„BX_}Ew¿![zmŗ͍StgĢKʶ*f\2ԨN!b[-z6 g[oq`1McTKOX(qI`:Z֓b5q\#DlJ*2Hƙi̛^9<9/n'?B'R2"L W8CQ>j`;jVB( 9rHNxbX#m41rPZh$>1ŦM8|cе{|t>%qt6(޺4]n`[/TYq~g/Wj"%6∧Ԛ<ͤblFeUU41} <hj!ÌfxE5. OFD:C,Lm !xyߢ_Iǡznr<=a7, 6c6aA' uĸaI)'N endstream endobj 50 0 obj <>stream HWnF}W/hCQꢠ%Jb!I;w{' 13;;s Ï߄Q\OW׷׿Z{l«ff`^]^ٯ~zTڃo"#̄54H .i_FF+wކӘ%;I-uwjwT":"Z\ Ӌ %֎@?vלyOc$/~ Hy;! Dy"ZvpO%jt: (k@mjRW7_z3޾}=w?BR3.1&n_MSaيlޖɂ)²|~5jY,@$]]LƧhS?8옎9I)W7asw 0SfPlvpy3֔cn%j΋84ȬWFzEad O:ܦoc. [(P ao>p!Cu}Tŧ;eEPW?_!kiȭYqeLJRǟR`<hw.Ht9Hj $Q+s˴d   )Kx2:hf0)5 HPt1)4R`1(iȏaڴ3&J|RcbqNQ۵iB$<jN6m=mF4r;rp6CmitB ib|ˆ:"hU4Xa0I?#Icaxr䀜BK*y|HؽR)#`i* T N" ~O晽3f:g RZH`69R:%xI#P tQ~K\JȀbʫt)X!LZ`Yַ62 R;Ό,@+2olshV7LqΨ@?]!0㿫η'A*rդ0$!>c6s : 83cT! @³c6Q_-xivue꘨Yң;! iHyAtDl"ZD9=5`öYeʇ_ 1pG="CM"@v nn#6C lõwS?Hİ^A3Y* f</bq7ݱPW/R5sIexO2Bp+u A*D- 75^+pJRd\*30 8 e~TK xuqy?Bb C$>/։O3KaMElvSTRA"5TPzZ3+7z$S^q} ~L) b8UQ@S:ڧHA+tIjRYd)=s|랾f%ǙϺn:g J硈RV,Q7\Wn )1#JᕙkO1e`~8qnUbu\jOQ<0XTJi&_o龲훧".>q8\Ulg.=ўS6iC-GHVtP shgnBcNx晚YtmW f&XBnfk.ž̚U}x1bTѬ_10. :V T endstream endobj 51 0 obj <>stream HWYo6~S1R? }+^٫f-9[wxIq]p873`aMuF ‚'"TUWC;mۮ0U1M}W*~׳BT{؅Տb2nU̘3"Ur ج2"=~a ΢v{Ō)`h`Zq~^oxƒæؔs1N.N~ڏT{nAeu|&$L <@!Gb$*M]*:Ģ϶#+j8mwE7$IRaQ V][顷o.2b^)_fr( h}n`M*i6B4k݌j5c `uU@I6ܶEMQ+`E~'erǼzb!kj*}^O+Kt4$G8XnF9c‘3 SIQp}qj|̬5$L"m*\ǹzSlq:f4*}yVt11/F/?sz&|fS|B\o_*EAp CbVXg:b90hE'/m%$&Z)x7XU6mET86Sv`QYi'w] #k]ٿf!+f$ˢ>K`fdg IxkdnF8R'0)-o% VW(LA%==LNvrajAQXYƗ\kdmHƅ͵"j0M 1L"d:~n)p i<^V&D orBUz4,rxcYuL'.SE|sEr#9qOWpBe뻮bk|~ }̑4vS:aRg\ȭ:ŵJ6gW%e㰟 -S^Se1w}lT1=orv nW\fSR~zM7mmՍ5v ˢ[IbT mч2A=6kY(cN r #H|T}>FD$޴7߄GE1!VA ŏ`&N8٠\Le 5ֺfEXrx̌t]m`L:筍KH !s2}l$<ޔ(^NMHJ0 !S?^G0,CW i4=oxbBT[FF&$,WJGB}=4:QFcѥ9sʪ8C endstream endobj 52 0 obj <>stream HWKoFW77~iNrhd%f!('.Ey|3 #6YmݦyEswvI 7u (&))/ʀ ɍ,"5}7)R䤒$v~w: 1P,#Z g\mv>jJcVLQ3\vӄF0I vWsj/jd1c#,WjrN%nu% Dk,<rBF&Q[;ֹ΅j$4v[.QT?1j$t3EPlp%Ϗݾ6UVgW<м{ð>~h]EÚm|DG1ؓ.o`^u$J^( G7JB'01FfmB$՘}c0[m-&z\-zBP@ ϵn]{b"I,iK=Έi<8 3Ǽ L̶unu}OiJ!v=29_C?ʤM5F^8Bs`~]iQvˢ*I:w7O~NU g-*p޺8BvHw: MKd$fԸ~s J;lsQ _nX&8eٴ1cġemn8lNjY:b#I E/NejL(}ٌU6-)_Q;S>=GdHcj]#{̲iALnZr Eڿ"v}x :80Y$ΰ]J`՟_d/}-g3c!6\5-3`4ZRN_ҁWEr,W tpkuFFM5o@OkPK &<@Hedȏ*y-&Z AΞUr3D8x3Cu«I"5:|&"1W~ O35O~ Y)- :S!~A̸u(w%.x| ]6qr&w*,QaIe<UST INʴOY,u ɏ%'^@5Su⸸3=oˋ<8U/0,w9=^s͌J&p{1|LWZCEQ}>stream HWn7}W  P4@@+;$:1P Cg9sx=FT 7mcn0Of$´D"*sj#A쮮lv3Xi̼d|2TTN%"<==.c=7o޼~7!%iHӊq.IO8 6fDT{ISY)j/Khm`4v] )n<2M 2=v5?$" SH4R?Ka”P\ D۔b]}7vW.% Aג?nG`ZTE vnP :VqH,e&xlRaqEx == 2cnQ g %&=t8]ApPp d&GE(2sRHd}pb$bPN{l5Zdе~UmUskiU 2 L< ʧKP(M22:!d*󤦪i$+4G{qw2yC4 (+Wua$K6N. 4̥%Ձ)ݏc?q eL;s0̐aibܚi$Bg-#3UChבmîL(5IkCOA H@4년}^b]4f =0^¬ɹ=]ebJTp b,ͣ=6 85G@Mx:v I'Bm ݢBFFCH'942peİ,s;S{|sKgZ)K&TF;tt.Qd aHj]4c#I20c+~A"n.Iačoz'v'0wC#}w8g=MK™~l9L*%Z1p$3EC;Ecg!Ez9lgx ]/5K<5A&`;bz. {I8P<5;Ќ/OU(;PIq*y@ˑNݹ 81nAOYzRu1H5 SW'$A tOTJǟa޸Hآt:yk2P:I֏e*BEtN1ڠ8l+S?]&:0Ò01^5 0XsiN4vp.10MiQ|hOP9w@]M^`'݋C9DJr%-p] -zBC졞p؂:*x6*&Y0\s <&NY Ò r2y$榿e<M]?œ6blKrө}B U [E 9f6S^\v-oJŒ0H: K~NK^v x?;VS,$2hч!E>YZ  VcZy#*q,tl@" >>stream 01000402000101010E48696464656E486F727A4F436C0001010142F81BF81C8B 0C1EF81D01F81E02F81E03F81804F81F0C158B8BFA7CFA7C058C0C1F8C0C221D 008C995C0C238C961D008C995C0EF77A0FF77D11F77B0C25F7830C2400060101 060E4E5C697F41646F62654964656E74697479436F7079726967687420323030 322041646F62652053797374656D7320496E636F72706F72617465642E20416C 6C205269676874732052657365727665642E2048696464656E20486F727A4F43 6C2F46535479706520382064656648696464656E486F727A4F436C2D44696E67 62617473000000000000010101020E0001010109F8200C269DF79012FB8E8B1C 05468B069F0A9F0B8C0C11FA7C14> endstr endstream endobj 55 0 obj <>stream Hd͊zy8 >sRhF^#y QG#Oç==o/ϧ;c_mӷKv|~_oo~y>}~W=|z>{O݇q~?>Ï?o+~ߒ~;%zΏx߽w;>lp?(O?{wٸ^ PZUuTGu^5P5FjFDMԤU PjVjUmFmک]uPuNNE]E5|| _#_k55|| _#_k55|| _#_k55|| _#_k5Z||-_+_kZ||-_+_kZ||-_+_kZ||-_+_ku:||_'_uu:||_'_uu:||_'_uu:||_'_uz||=_/_z||=_/_z||=_/_z||=_/_ || ߀o77 || ߀o77 || ߀o77 || ߀o77 KG#(~? ?G#(~? ?G#(~? ?G#(~? ?z $߄o77MM&|| $߄o77MM&|| $߄o77MM&|| $߄o77MM&||3,ߌo77f||3,ߌo77f||3,ߌo77f||3,ߌo77f|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|ۯ\t;]~~߅ww;]~~߅ww;]~~߅ww;]~~߅w߁w;;|C߁w;;|C߁w;;|C߁w;;|C߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S ߅w]..|K ߅w]..|K ߅w]..|K ߅w]..|?|x>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 22264/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream 2  d~fT-<;%/4x~=B%W^8F Kb¯y4FYv) &}nk9Jq+|@wA죪c6Ir\ΝqZQ#Ay< ݣSyozDW3cR)RvQ9Dk,_s8> x#NV}> 1L ¿xAx#*W6"AatzoDEi kSnYޘCȪn@]sS!cC\41͆tNIlϓ:Ҡj҂y6۰!1P2T 2|A-YGpimZ)age![o&R8<,S}1zZLYtͪ5 nUft03tśZ 0 |]K?#̲]ʝLhB+o{O}+R)kfnl(Bu>3`4ct=3,i*>ݻ#ϟjqJP-([YozӍ뫂۠$?5 0(](d'A a7$~7MRΪ,(1W4T)3& JK] %ג}9XD7}'?לkIue=CiҖb}A(P88ڐr~ "Η+BףŽHpaHWH1Å'̞JiCP$n u׳⼥~]:h1E\%BA='ׁה'01Ēƫ{K)xEd>ʈ/;j$'gplYw] e9*u\@|BAhGx;x7ZO?+lz|NSs ]Uܨo54_%+3>X L:d`lZ&Ia-'XpHߗ頉1J4#s{jMD3YD\llϡzh'g &O:HJfE~"=䵾""biyM74/tiD@R¬T#at) &ue3"/]w{q&-1bR)k'鼵+< ayjD}o4YjWj}1'eވu[{NßLyi7 Kړ 'g ~RWeيuH #.|"Ջ/ؤ_pФR Ezފˤ$/E͡;:K\i~\VH^t:Tb514Iϲ cHk8h8GBɂ7&o[y #2˜kZ<.pn`/gk@s1A —[>]~E|wPdǗQ!_ }t`U-M]9$S.!a41H:QX%+sf*FO[zRbvHR,mf KdY_]HTI!"ʣH֞*<}t:E?g̳<$('Le5C-`73r_6mV>I $s%6Yjkʋ:}~EeE@tBw-a]W%M/RN#5sɰ4o-\') H,2ݟ/xdC;o#uku-v89Cf^Nx㔸/c>s~n7N$sգІ.P$se`u8qHf`o_t OǢaKdN8T!}'Ί#Kިq1SqkiGI&bZ84"\Zpg =W+5h}׏\ԏSnBH>f9Xm$Mý{}6(G()1,b0ra8]ip*Xc.uQvfl6Zk=j֖r\PhXAZav |)U߫x rbpp/G4)r>Ub;xIauIv\`dFX>KxRE̬sA:1/9EfE!oiW ٢ Ezдu*Y?'%;ݛ(D╛f?z/. Y6/'n3~_aE(6--F[7ecC|.k F$Zmbc( CӜu~!3NJO:w<ۓJ¸g2RyѶ5uE*{1)!-T3cp tΘy5-1 MF>125! S%Tز & )V_B=Q.%1?bΑfZW'K^l;^变lLm܉JJFiZ_Țs_tΕYFRZ`\H\^AmNJw@^\- ׫1(+[䢭0WZE1 zpvsR򃴥jD1};YY-nwyg'7ziw$m$Z#ld`@n (8rM R_|!%a YA THjb$`ldYG&s=F*$v[;xlPQv ;9IH4qm/G%=R>*SROz$'%/?eXBfĐ3Qɧj[cCjz{imـWiR)ʅpk}ұ„ ~[> l/Zo{F :~$"$OoPT@6yx'Oڝ}l "muyXՠܮJܯ,6 ]MU73O 3Nf.9H0+3p"W7uՐ&x/1 '1sΞSZmԖ%/f@=O Ii it |;M /zUp8_-S#dRT ˰7 X7R@DlOZ@^|]~ e:5 ]Ȣ;@rin1fh#f?( !4a kQVM+Cau& !B=&J |q }cAFEYhHJܻwP/:pk0v*:0M=x $D*HNW]ppwY-_ ڴu!ƿ iqV=ŏO9>pw9=?q**}'QmH帀k@OK $BdŭМpdC۫ h9BQ_0KEi |w!{lj)ȳ/ 0?8 o%YRVzEyl9ntLe:uG`կ3q QLx =s so@lJN9앪{ZA[5A&O,k'hhugYG?7y=R㊓ ؍Z`.nn|,?ezdo<=dkSQy.XL:ꭓ}p uWC}?~&iE!י,<ōk0>OZ*,J"1!,?yg< b.ye6=Y_nDih^o֏mf J&Bߊv l}`|BeSX9 ά "tJCa&;Ig!*RQ&5vS-S;B_m?¯U @Әվj`\lj !qMVmJdk*8akS g_Z[#8R:vg!afb*e:2:8:~< wdz`;y&VudTnYEAwU?1/!38 +D@Fg45׻_)rښ ^g\.c1Z%UoKfU <)іX{FĻg?&nKӝ uSL{~$fжqli_بlG2,)muY7x*y'sl(1r+"'%md=zÙ<դ2sfZj'mf4Cכ74. LR ^m?Ŗxrp0,q笅'AGM9'u $* vjțTbHwu=>ώ.6)`N  Bx'*875ef4ET@yPB *َf ::aXE*VZkHх~l.K&r0#d nƳ}f'Иw2Pfh9Zmq%ҨOU'I"a8J)ljAX.e<]˞ 1}_>r=[4Tޛ4*E}IB^&԰S ~ AE_TGѴF:sXxzǐ=t.M p(+JRiR6g'Ppx0nhd(,㋥܏s(yQ m&dRP_@!CƸ JAjԤDSKs3]:wY8AbEcZr"$l"P+H 4ոj  <͉ @GD/MEnP4e3`\Iz@T/Qۯ'_^GtclF3ܛcB9rzԹLeȈ܊ "z0$a^w`>z%"ʌi@CQs9Q^GJhW4 G.8ɶb4/]:/Z!y &Βt$d^܄mO.&r\ܕ\J|(~Jm+{.Y4(l6Oے>=r?ݖ -{]\ʫ!+vKk`c;w q\q&&h#@ M0@>*މQ>;%Txſs|C[{)(v5V5k99]+.)B? L!tЃkp)OD-6SsAX rb聬{_-`^$/c7WΟ0*tjj}'Mn5 _RK "*~tV'%ێ rՏ2A&grL0r:ȃ?~r5z~zgJ xc*o7Z &]d̋Q.Xr1[WO^:^p?{+꼢=wwٞ=_va^L=wRg%,{.̪z$m]jޙ>7Qb3Š4:D<]햵Ē̢~0Xl/ I;=J?r)b6W,1m-(08ߛ„͆!qŅLTFnB^'WytHy$dIV^wXX*K>3mϢRFc\.yGfqOPƕVcz†HZyW eMbNsM3 MK ՆYoaMGoz$"4icڥ9Ru;Q}/+'#sxPQ:2κsEQXh񍶇%)T4i!M J Y900pԝnVϕi^y8z-8:>ϋĹ+BrT,ZmdeC7>ѐR 1~-Λݱietl2սddw&ysm:!B%Z23kwfT''ȅ䠁I0823G3+H%$hi8XaZ'~xBD6uؙ$WN߇M& vSxb :÷1X@J镭'>aE\"h̴Bg7θ]E~ |< c>sjZ ş# iE'vd⋐" ߼lwWN&G=6h/A Lcݍֵꄤ|8^=i,l6)F QtYvUb g@Թs靘,Q,*;[r2ĭ=/[C'`&yd&ڹ>|C8?Ȣ[)TB5}H7+,CeZoH~[R%F"O~~&#.•uf 2(g7 bzz j2ۅmu٩+8ms.E4s"ݬ_y`ӻ(*aZibk lS=jҭG 3FoL0FC[7)[P8㮧Bg/CqزP߹pS+*k5Mnߢ۹R.Dp>/DrmoTWSg 8ʵf@DEB0t5f'^9;i`r`.ɱ$yKI$8cu=)ZKqγQ8w`Q~u;K_TWR?D۝ r`_cr&P6x5W @"l dL:ٹ+%V||&fjHkIWGrsVRb9fwAD&#钩l|;\[1IF1Gu.fqM *fwH#FS:(F|-yۺzGw;#> 5kW D,,M}lXeH$>g5w}y+W4=tdHWU[WZHԧ& e7  +.s6,G}`B6[g5ɫ <+rIS G u, /J {=zJnO5-{[Xj>-Il0- KN)i^>?K~[:nxR!0?h/Nԛ5Ȱ%" u7U]PPY*C*]ad2ZJ5شu\<e:tQ3O҄<28jӵʐʹWzFYBv'-JޥBۆCVb셨K%t=H⻍* |-=LDOଂEпHMr-tVn'T^=湁9 v"޴cS#>0$n3g <wS7mt { %a S 9犊p/VWSJU0ݡ-!e yM`ߕSFΰ M,mj;zh#ti3C0Gq\]Ӆw1p3`lqaUf/ym;/ !Mkbh<3HGi2< ^p$ȩ4 O;Cֆ,Xq3;2TDGn?rwu|5Ya+/l}@ dyI:2BЕ7iCJ8PŠaJoe~IgPr$Rn r3|[R@sc(eui qy\\AsHף7["1_iQ_k3D])je/k@)<25uߕ%ǻЃmM^ݛrq=LQ*٫E8Qwn%'$X[([`eYp7P? hwЙBfPԲ {r1Ga vGR}< Λ: w V3SDiծp@e\6r7kA5 KGzZw 'I{~6Ę4˞l^%~Vw ^N׾"+~Q>CsYv)c8@nlEv: Oyj*:zU|Ղn[c立ZrT2O3.RU8_S%fz:+\BWgC$wdVƳ./ί;& ۱*%(ߺ4Êf :i)VolԠnRt)cLޓOE0aKH#ЂQtA=Ʃf#Nz>OeamhD\qWR#^7[٘KC1 ^aae5B΀#焾Mt*)H`2s;(!BtQj)-e]p YCz_`Ikõx <˧YeX*1wD 9^!IO)oz#W0$;x"jQtHBʖ|їy<\B)tvVGzIG!W'a]qU]a\Vj7ej466$9/--$0@ $?w-2e=CgNJRV' `=[;%<7ə/*-꧎gzG QsE?x-qNI 5b>iuA8T &>^#Sr+: mO: Gdt?e^yz! Ck1?G*iLbڑ&AꝻ%?$ʋwyT33",a8,Q?kG}u9)g-儷v;ty4gyAvYa="h@§B_Z7oA,?z}!zcĽ dՄ54Z2AZ9BϚ[yR<2y^w6P[6]_v3`)/v& tdXuKr+b~/HOA,̨)HBb1@lfę nd"W9bpJ 9I7'lesj6}J`ۈE{HI\%*clb /$ uU[K)sCH^ա&~kGϽg+reE.dؑZݪpk`}OK4_1 5W@Iͦ:ҹ-S|aCJF`&<6&3.*4Zβ6jyzٖoL^]0W8g|=sǤ+i_:x/dR0pDYXJu1P=e K6>duS(иwX $˟CuZ(Fo!\n!Ghw@M*t_eڨ]"xL Yn?x^ivc` wφ, bknnx­$8*O5+¾Ȃ¸:})_T+R؛oH]DHㄹzZs nju mwiuLH^ kI{!OSݥ:hb*qFp1"Dd?̚8n{X S!kwH. hƆ`ӝd[=a@ylrSZ LmOAV-$D, 5%RE`Na!ʜ6,fw+A/GB6}Ѻ#ëlryiALo`I$tyT :ruڤ??iozN(4(9x?Ho\ÇLb'K`=qqB?h)(j)w^PmTx_sdA-]}s|o9J1!:{Ix܋5h-ኰwn?CTܧKC5}?(Z&$719 +*GAPp UiRJP`Mxrʯwtw`h`Ydwyb̥bЧA T".Asp8˿r$VdP [oGь04fkv=lX|.\ݖ  ͘vIa/B38#]m{Y z}bg(^Vڅ8Nv^ Y~ZMi|%tJwPXT_ 27M1%(D2/y[X-a5u7ѧz+<\PP` zȄi-e3+Z $$IkMAW͌ 1Ā,3 ]NEk!;Uݗ$s9IB?T LMg,LaT5]0F*tȞkDҝuES.BMtYk&|J8=Džz&Q8o|L NyWҁѻ02NUF)><ɯ_R5+ɡY<^7q.%I[,- ee-Lpx  =j^D`ބTJvl/_&uȣH=u>XDJwsip Vxo0 U@ fO>;bAX:y۬Rv*Hl 썡SޙKyߊPl*Eľ6b)7|pϸ@n9412=|Qd삠0G~9҄,bc\0^Z!A0甿Ny_ƽ_W~؞&1 E቎8:GmdvZW3{5sņ[a?׶v-q'$ݝ͘A'Ԫ*Q͋іz;o|C*)mxkyx"ט?F5pì@JTDG{x0pm3e>{Ifb h&Ηλ,'P¨{O+XclE N߳L::-@{_)KH#,Ş5)?:(l9EЬ֧= B4,\Q5Ty8?0$ӥ`ô9g[D۽XwU'f=Sw%RZfo "OI@'Nf2gb *:F974z)߈6wfѥjoa銓JSsDdW>`-!f!5̕b̞y(kKrs3:>_bRJ,AoYT6e1n?u>ԙ:SDGmo 4xBB*/%ӡ0&5<`N^KkR{?%Wl[`ȑ+J}Z-<^}F"9Ճ "!>u+aZ^nbQT~(!)豵Anܷl3ڂe^, >tex⫍/ݎL2Y~I"KL 14;Gn;6PY 13FLI(@b2PD*QߴH?^RҸe$Y1-ic9&Ǝc\R5Od]e'^bg}4( 齅V˼)4D0oKh4SLΨ{zzKa&kWzw}eRA,"M/=%XY~n"UE@Au/1ģ^nU (3o7A|Mͬ(<3_EZ˞8@6u)~цd#޶(QtcLשK{N{+ٷ#Ӻ ]ZjC-g{ŲWsTщ` +Ys6Z{F[\kX;[+>D8@N2x_X޿.U`-,ړI%ZҔFRt<iO;~> n_Xj?Uд9 S~:e XՕϸvLU ?jsYhw!S8~sZx8}.aj.(u?Σj+'b yjyLEc.f`@g8\ S5õՋع 7W;,H".BgyD Et=IMéM>ʃl *t,F<ңİ@Pq CH&U sUI| ,RסQ q "ԅ:kl~!=H KZ_4#?Et܎Hxť_%r DQ`چU`9uAp?IS gɲ f|+ '*3k`:(b\rb x(k_CAY,ݲ"PnWwqHiђ$rWt~z9LKD4GnϋȔ9Ҟ7n't K-e8'=vj}(5vxu֐9ɤ+ {-&h75jHӲwTqfaS3Q,C&Q8/na`0H MJ:(;ը,HbVӴ#,lҼha9SK/e*AO۾;vL!0OjI3bn m.+qPMU$nJF>i$GpϘ D+h;:a'*B\R(tZU}[)YZMﺳE)4x}n*S8b.\H3iǡ\,( "wp9r >3v=g*ZHٟ==OD“kؠ#֢Sע94G;TkHx.z*- 7x`pe+u"C:ϊQ[$6W͊k>!AŰPx?Kb<#a'n5$f MFŖFdK> &n-) X1`L?IOQ xvR"[8xBEeG!@^BE1 xRO,>Z1U Vtt5D"0TbwY}^m?rg6Tc+@nng+d\p'+azE PT;|(\7c؛[^GơPW?> t ~RV܇t+eEώ"Tj1Fcg0pY6/FtբMXAi)obG13T1ΤaȈ;7D*(Ly_5~ BcN ؤ4;yx` a_t8 }7ֲ[w8[4&ll` qʘHQPbjl_׫o@rŠ1RLМh候D{3P߶Ȟ}6a?v ffnXactH68;@Ř)rC${퉋{A⯂S\ޣ ޮ3AJ$6bj.| 5?|:+y(XcLz$*»K{i &:N' o+M]QR b99{̿C9DN};"NӬÐy>$d,{Ƙ> T>k6&c8Cp rl5r29O:y̲fmV\63@F0Znl!>rǻX*dܵIS"H|4mJgƀ2pS^AO6:6z-g$-J X&z,^ە)} F{)0rlC8g 3C&D"_;`SNZ0[?CȯE-(UeDB5N4B/-#RO0?V3YRF ;%r~:Z()5 6UD45XEg׻؆ffL\ƒ\\m ?dYeH#sbfa{nsGG[½8:*k Ĺ'?_ŷ/ir<[!_HɚyC__JYpK<#ѶpD+l6A*I0{ZËI$<9]|:j&z6Zl"[r@iMU:C endstream endobj 57 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr>colrljp2cOQ/>>R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t !  h@  l|!     endstream endobj 58 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrrjp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  & :@ @  >    endstream endobj 59 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr1colrjp2cOQ/11R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t  $ :@ m B % k @|"@ i  :z   endstream endobj 60 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr&colrojp2cOQ/&&R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t ! @  Ƞ>`  $B   endstream endobj 61 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr:(colrjp2cOQ/(:(:R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴPC $" ( |!@|!   :l|"ր %ۛTȁ 3a  endstream endobj 1 0 obj <>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Rotate 0/Type/Page>> endobj 2 0 obj <>stream q 0.18 0.18 0.18 rg 595.1999969 0 0 840.9600067 0 0 cm /Im0 Do Q q 14.3999939 0 0 12.4799957 60 787.6799927 cm /Im1 Do Q q 14.3999939 0 0 15.3600006 572.6399994 784.8000031 cm /Im2 Do Q q 12.9600067 0 0 21.1199951 0 728.1600037 cm /Im3 Do Q q 12.9600067 0 0 25.9199982 0 6.2400055 cm /Im4 Do Q BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0092 Tc 3 Tr 9.9 0 0 9.9 55.64 751.44 Tm (434 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0078 Tc 8.8 0 0 8.8 229.76 751.92 Tm (S. )Tj EMC /Suspect <>BDC 0.0483 Tc 1.377 0 Td (PEDERSEN, )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 9.0571 0 0 8.8 296.55 751.92 Tm (G. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0433 Tc 8.8 0 0 8.8 311 751.92 Tm (FUGLSANG )Tj EMC /Suspect <>BDC /C0_0 1 Tf 0 Tc 7.2 0 0 10.08 55.69 722.17 Tm <007E0020>Tj EMC /Suspect <>BDC /T1_0 1 Tf -0.0056 Tc 11.4 0 0 11.4 75.18 733.68 Tm (,. )Tj EMC ET BT /T1_0 1 Tf 0 Tc 5.3001 0 0 5.3001 56.11 717.85 Tm (Q )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.05 Tc 5.7835 0 0 4.3001 75 720.73 Tm (Xl )Tj EMC /Suspect <>BDC /T1_0 1 Tf 0 Tc 12.1 0 0 12.1 56.14 711.12 Tm (w )Tj EMC /Suspect <>BDC 0.05 Tc 5.1208 0 0 4.4001 75.33 709.68 Tm (20 )Tj EMC /Suspect <>BDC /T1_2 1 Tf -0.035 Tc 5.5495 0 0 6.7 56.03 705.36 Tm (;!\\; )Tj EMC ET BT /T1_0 1 Tf 0 Tc 8.8 0 0 8.8 56.11 699.61 Tm (z )Tj /T1_2 1 Tf -0.035 Tc 10.2685 0 0 13.6 75.59 699.61 Tm (,. )Tj ET BT /Suspect <>BDC /C0_0 1 Tf 0 Tc 5.76 0 0 10.56 56.17 688.56 Tm <007E0020>Tj EMC /Suspect <>BDC /T1_2 1 Tf 0.05 Tc 9.6149 0 0 4.2 75.1 687.61 Tm (II )Tj EMC /Suspect <>BDC /T1_3 1 Tf 5.9109 0 0 5.1 55.99 684.73 Tm (Ul )Tj EMC ET BT /T1_0 1 Tf -0.0232 Tc 8.4 0 0 8.4 56.08 679.92 Tm (a: )Tj ET BT /Suspect <>BDC /T1_3 1 Tf 0.05 Tc 5.529 0 0 4.7 56.02 675.61 Tm (\(,\) )Tj EMC /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 12.5002 0 0 25.6 75.1 676.56 Tm (.. )Tj EMC /Suspect <>BDC /T1_2 1 Tf 0.0497 Tc 4.8001 0 0 4.8001 56.51 669.36 Tm (..J )Tj EMC /Suspect <>BDC /T1_0 1 Tf 0 Tc 6.8001 0 0 6.8001 56.57 664.09 Tm (0 )Tj EMC /Suspect <>BDC /T1_2 1 Tf -0.035 Tc 10.3082 0 0 23 75.08 665.05 Tm (.. )Tj EMC /Suspect <>BDC /T1_0 1 Tf 5.0607 0 0 7.2 56.51 658.33 Tm (::E )Tj EMC ET BT /T1_2 1 Tf 0 Tc 6.9001 0 0 6.9001 57.92 652.56 Tm (E )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 6.4207 0 0 7.9001 56.48 646.33 Tm (::J )Tj EMC /Suspect <>BDC /T1_2 1 Tf 7.5666 0 0 13.1 75.24 651.61 Tm (\225\225 )Tj EMC /Suspect <>BDC /T1_0 1 Tf 0 Tc 6.8001 0 0 6.8001 56.57 641.05 Tm (0 )Tj EMC /Suspect <>BDC /T1_1 1 Tf -0.035 Tc 6.4391 0 0 8.7 56.58 636.73 Tm (en )Tj EMC /Suspect <>BDC /T1_2 1 Tf 6.8559 0 0 7.8001 56.45 630.48 Tm (I= )Tj EMC ET BT 0.141 0.141 0.137 rg /T1_0 1 Tf -0.0232 Tc 8.4 0 0 8.4 56.56 625.68 Tm (a: )Tj ET BT /Suspect <>BDC 0.216 0.216 0.212 rg /T1_0 1 Tf 0 Tc 6.8001 0 0 6.8001 56.57 620.41 Tm (0 )Tj EMC /Suspect <>BDC 6.1 0 0 6.1 57.06 615.61 Tm (0 )Tj EMC /Suspect <>BDC /T1_2 1 Tf 0.05 Tc 5.2333 0 0 4.8001 56.5 609.85 Tm (..J )Tj EMC /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0 Tc 6.8001 0 0 6.8001 57.05 604.56 Tm (0 )Tj EMC /Suspect <>BDC 0.082 0.082 0.078 rg -0.035 Tc 5.0607 0 0 7.2 56.99 598.8 Tm (::E )Tj EMC /Suspect <>BDC 0.216 0.216 0.212 rg -0.022 Tc 11.7 0 0 11.7 56.88 592.56 Tm (.s )Tj EMC ET BT /T1_0 1 Tf 0 Tc 8.8 0 0 8.8 57.03 585.85 Tm (c )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 5.706 0 0 6.7 56.98 581.53 Tm (::;, )Tj EMC /Suspect <>BDC 3.9658 0 0 6 57.08 575.76 Tm (CD )Tj EMC /Suspect <>BDC /T1_2 1 Tf 0.0189 Tc 6.6 0 0 6.6 105.94 580.56 Tm (BOP )Tj EMC /Suspect <>BDC 0.05 Tc 6.6959 0 0 6.6 121.8 580.56 Tm (\(nMOL )Tj EMC /Suspect <>BDC 0.0372 Tc 6.6 0 0 6.6 145.35 580.56 Tm (CORTISOUmMOL )Tj EMC ET BT /T1_2 1 Tf 0.0177 Tc 6.6 0 0 6.6 204.387 580.56 Tm (CREATININE)Tj 0.333 g 0 Tc 6.197 0 Td (/)Tj 0.216 0.216 0.212 rg -0.0069 Tc 0.339 0 Td (DAY\) )Tj /T1_0 1 Tf -0.0015 Tc 8.3 0 0 8.3 55.64 560.89 Tm (Fig. )Tj /T1_2 1 Tf 0.05 Tc 7.8667 0 0 7.8001 72.26 560.89 Tm (I. )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.0253 Tc 8.3 0 0 8.3 85.43 560.89 Tm (Urine )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0127 Tc 8.3 0 0 8.3 106.9602 560.89 Tm (cortisol )Tj 0.333 g 0 Tc 3.411 0 Td (e)Tj 0.216 0.216 0.212 rg 0.0045 Tc 0.412 0 Td (xcretion )Tj 0.333 g 0 Tc 3.575 0 Td (s)Tj 0.216 0.216 0.212 rg 0.0143 Tc 0.417 0 Td (tandardized )Tj 0.0146 Tc 5.139 0 Td (for )Tj 0.0147 Tc 1.505 0 Td (creatinine )Tj -0.0006 Tc 4.278 0 Td (excre)Tj 0.082 0.082 0.078 rg 0 Tc 2.139 0 Td (\255)Tj 0.216 0.216 0.212 rg 0.0033 Tc -27.055 -1.1 Td (tion )Tj -0.009 Tc 2.076 0 Td (in )Tj 0.0188 Tc 1.336 0 Td (thirty )Tj 0.0145 Tc 2.711 0 Td (children )Tj 0.0104 Tc 3.882 0 Td (treated )Tj -0.0122 Tc 3.355 0 Td (with )Tj 0.0084 Tc 2.316 0 Td (beclomethasone )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0173 Tc 8.3 0 0 8.3 243.7525 551.76 Tm (\(BOP\) )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.4599 0 0 8.3 269.67 551.76 Tm (and )Tj 0.0093 Tc 8.3 0 0 8.3 55.69 543.12 Tm (budesonide )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0192 Tc 8.3 0 0 8.3 96.858 543.12 Tm (\(BUD\) )Tj EMC ET BT /T1_0 1 Tf -0.009 Tc 8.3 0 0 8.3 123.7666 543.12 Tm (in )Tj 0 Tc 1.098 0 Td (a )Tj 0.0158 Tc 0.876 0 Td (randomized )Tj -0.0025 Tc 5.196 0 Td (cross)Tj 0.333 g 0 Tc 2.022 0 Td (-)Tj 0.216 0.216 0.212 rg 0.0124 Tc 0.349 0 Td (over )Tj 0.0287 Tc 2.135 0 Td (study)Tj 0.333 g 0 Tc 2.307 0 Td (. )Tj 0.216 0.216 0.212 rg 0.0329 Tc 0.535 0 Td (Each )Tj -0.0044 Tc 2.49 0 Td (value )Tj -0.0002 Tc -25.213 -1.099 Td (represents )Tj 0.0273 Tc 4.394 0 Td (the )Tj 0.013 Tc 1.561 0 Td (mean )Tj 0.05 Tc 8.9033 0 0 8.3 126.16 534 Tm (of )Tj 0.333 g 0 Tc 8.3 0 0 8.3 135.82 534 Tm (t)Tj 0.216 0.216 0.212 rg -0.0031 Tc 0.29 0 Td (wo )Tj 0.0152 Tc 1.557 0 Td (24-hour )Tj 0.0074 Tc 3.534 0 Td (urine )Tj 0.006 Tc 2.357 0 Td (sample)Tj 0.333 g 0 Tc 2.892 0 Td (s)Tj 0.216 0.216 0.212 rg 0.399 0 Td (. )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.05 Tc 13.97 0 0 8.3 232.58 534 Tm (\225, )Tj EMC ET BT 0.333 g /T1_0 1 Tf 0 Tc 9.2 0 0 9.2 242.84 534 Tm (+)Tj 0.216 0.216 0.212 rg 0.772 0 Td (, )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 12.2 0 0 12.2 252.83 534 Tm (e )Tj EMC ET BT 0.333 g /T1_2 1 Tf 7 0 0 7 261.01 534 Tm (= )Tj 0.216 0.216 0.212 rg /T1_0 1 Tf -0.0043 Tc 8.3 0 0 8.3 267.76 534 Tm (chil\255)Tj 0.0279 Tc -25.619 -1.098 Td (dren )Tj -0.009 Tc 2.206 0 Td (receiving )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0096 Tc 8.3 0 0 8.3 105.9349 524.8866 Tm (800)Tj 0.333 g 0 Tc 1.506 0 Td (, )Tj EMC /Suspect <>BDC 0.216 0.216 0.212 rg -0.035 Tc 8.1597 0 0 8.3 123.56 524.89 Tm (1000 )Tj EMC ET BT /T1_0 1 Tf 0.0358 Tc 8.3 0 0 8.3 141.52 524.89 Tm (and )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.026 Tc 8.3 0 0 8.3 157.6303 524.89 Tm (1200 )Tj EMC /Suspect <>BDC -0.035 Tc 6.0062 0 0 8.3 175.47 524.89 Tm (118 )Tj EMC ET BT /T1_0 1 Tf 0.0316 Tc 8.3 0 0 8.3 186.73 524.89 Tm (per )Tj 0.017 Tc 1.608 0 Td (day, )Tj 0 Tc 2.148 0 Td (r)Tj 0.333 g 0.28 0 Td (e)Tj 0.216 0.216 0.212 rg -0.0037 Tc 0.459 0 Td (spectively)Tj 0.333 g 0 Tc 4.042 0 Td (. )Tj 0.216 0.216 0.212 rg /T1_1 1 Tf 0.0201 Tc 10.2 0 0 10.2 55.18 493.69 Tm (Statistic)Tj 0.333 g 0 Tc 3.346 0 Td (s )Tj 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0174 Tc -2.36 -1.6 Td (Wilcoxon's )Tj 0.0356 Tc 4.897 0 Td (rank )Tj 0.0267 Tc 2.152 0 Td (sum )Tj 0.0094 Tc 1.941 0 Td (test )Tj -0.0218 Tc 1.695 0 Td (was )Tj 0.0013 Tc 1.789 0 Td (used )Tj 0.05 Tc 10.4772 0 0 10.2 213.57 477.37 Tm (to )Tj 0.0341 Tc 10.2 0 0 10.2 224.54 477.37 Tm (compare )Tj 0.141 0.141 0.137 rg 0.05 Tc 10.377 0 0 10.2 263.9 477.37 Tm (data )Tj 0.216 0.216 0.212 rg 0.0048 Tc 10.2 0 0 10.2 55.09 466.33 Tm (from )Tj 0.0265 Tc 2.55 0 Td (the )Tj 0.0281 Tc 1.788 0 Td (two )Tj 0.021 Tc 2.075 0 Td (periods )Tj 0.0134 Tc 3.565 0 Td (and )Tj 0 Tc 2.035 0 Td (p )Tj 0.333 g 0.699 0 Td (< )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.0116 Tc 9.8 0 0 9.8 193.34 466.33 Tm (0.05 )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0017 Tc 10.2 0 0 10.2 215.99 466.33 Tm (was )Tj 0.0181 Tc 2.015 0 Td (considered )Tj 0.0076 Tc -17.792 -1.036 Td (statistically )Tj 0.0027 Tc 4.941 0 Td (significant. )Tj -0.0076 Tc 4.859 0 Td (Values )Tj 0.0313 Tc 3.051 0 Td (are )Tj 0.0016 Tc 1.554 0 Td (given )Tj -0.0079 Tc 2.495 0 Td (in )Tj 0.0265 Tc 1.135 0 Td (the )Tj 0.0037 Tc 1.6 0 Td (text )Tj 0.0261 Tc 1.827 0 Td (as )Tj 0.0021 Tc -21.451 -1.082 Td (mean )Tj 0.05 Tc 10.3398 0 0 10.2 81.01 444.72 Tm (and )Tj -0.0043 Tc 10.2 0 0 10.2 101.27 444.72 Tm (range. )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.0043 Tc 10.2 0 0 10.2 153.545 417.3738 Tm (Results )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0309 Tc 10.2 0 0 10.2 64.2236 401.0538 Tm (Thirty )Tj 0.0193 Tc 3.011 0 Td (children )Tj 0.0353 Tc 3.765 0 Td (comp)Tj 0.082 0.082 0.078 rg 0 Tc 2.354 0 Td (l)Tj 0.216 0.216 0.212 rg 0.017 Tc 0.233 0 Td (eted )Tj 0.0265 Tc 2.079 0 Td (the )Tj 0.0113 Tc 1.635 0 Td (study. )Tj 0.0257 Tc 2.922 0 Td (One )Tj -0.0025 Tc 2.072 0 Td (girl )Tj 0.0017 Tc 1.749 0 Td (was )Tj 0.141 0.141 0.137 rg 0.0192 Tc -20.753 -1.083 Td (withdrawn )Tj 0.216 0.216 0.212 rg 0.0081 Tc 5.178 0 Td (because )Tj 0.05 Tc 11.1292 0 0 10.2 146.77 390 Tm (of )Tj 0.0174 Tc 10.2 0 0 10.2 162.62 390 Tm (acute )Tj 0.0257 Tc 2.823 0 Td (exacerbation )Tj 0.05 Tc 11.1292 0 0 10.2 253.33 390 Tm (of )Tj 0.0463 Tc 10.2 0 0 10.2 268.79 390 Tm (her )Tj 0.0388 Tc -20.997 -1.081 Td (asthma )Tj 0.0257 Tc 3.341 0 Td (during )Tj 0.0265 Tc 3.114 0 Td (the )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 10.3089 0 0 9.8 137.23 378.97 Tm (BUD )Tj EMC ET BT /T1_0 1 Tf 0.0128 Tc 10.2 0 0 10.2 163.22 378.97 Tm (period. )Tj 0.0328 Tc -9.653 -1.082 Td (Fourteen )Tj 0.0193 Tc 4.418 0 Td (children )Tj -0.0024 Tc 4.056 0 Td (were )Tj 0.141 0.141 0.137 rg 0.0183 Tc 2.587 0 Td (treated )Tj 0.216 0.216 0.212 rg 0.0056 Tc 3.53 0 Td (with )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0368 Tc 10.1 0 0 10.1 239.47 367.93 Tm (BDP )Tj EMC ET BT /T1_0 1 Tf 0.037 Tc 10.2 0 0 10.2 266.3 367.93 Tm (and )Tj 0.0033 Tc -20.804 -1.082 Td (sixteen )Tj 0.0212 Tc 3.401 0 Td (with )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.05 Tc 10.3089 0 0 9.8 112.75 356.89 Tm (BUD )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0351 Tc 10.2 0 0 10.2 140.54 356.89 Tm (during )Tj 0.05 Tc 3.302 0 Td (the )Tj 0.141 0.141 0.137 rg -0.007 Tc 1.826 0 Td (first )Tj 0.216 0.216 0.212 rg 0.0277 Tc 2.13 0 Td (period)Tj 0.082 0.082 0.078 rg 0 Tc 2.707 0 Td (. )Tj 0.216 0.216 0.212 rg 0.0387 Tc 0.778 0 Td (Neit)Tj 0.082 0.082 0.078 rg 0 Tc 1.829 0 Td (h)Tj 0.216 0.216 0.212 rg 0.0438 Tc 0.508 0 Td (er )Tj 0.0088 Tc -21.493 -1.035 Td (period )Tj 0.05 Tc 10.5727 0 0 10.2 86.78 346.33 Tm (or )Tj 10.481 0 0 10.2 101.18 346.33 Tm (ca)Tj 0.082 0.082 0.078 rg 10.7308 0 0 10.2 110.86 346.33 Tm (rr)Tj 0.216 0.216 0.212 rg 0.0153 Tc 10.2 0 0 10.2 118.55 346.33 Tm (y-over )Tj -0.0167 Tc 3.19 0 Td (effects )Tj -0.0024 Tc 3.069 0 Td (were )Tj 0.016 Tc 2.437 0 Td (found. )Tj 0 Tc 3.249 0 Td (T)Tj 0.082 0.082 0.078 rg 0.714 0 Td (h)Tj 0.216 0.216 0.212 rg 0.508 0 Td (e )Tj 0.0146 Tc 0.944 0 Td (indi\255)Tj 0.0099 Tc -20.371 -1.083 Td (vidual )Tj 0.0089 Tc 3.051 0 Td (daily )Tj 0.0144 Tc 2.54 0 Td (excretion )Tj 0.05 Tc 11.1292 0 0 10.2 156.37 335.28 Tm (of )Tj -0.0061 Tc 10.2 0 0 10.2 170.29 335.28 Tm (free )Tj 0.0186 Tc 2.025 0 Td (cortisol )Tj -0.0079 Tc 3.673 0 Td (in )Tj 0.0029 Tc 1.371 0 Td (the )Tj 0.0163 Tc 1.79 0 Td (urine )Tj 0.0257 Tc -20.245 -1.081 Td (during )Tj 0.0265 Tc 3.302 0 Td (the )Tj 0.0046 Tc 1.835 0 Td (two )Tj 0.0131 Tc 2.122 0 Td (periods )Tj -0.035 Tc 10.1489 0 0 10.2 164.56 324.25 Tm (is )Tj 0.0124 Tc 10.2 0 0 10.2 176.5 324.25 Tm (shown )Tj -0.035 Tc 10.5807 0 0 10.8 209.19 324.25 Tm (in )Tj -0.0105 Tc 10.2 0 0 10.2 223.09 324.25 Tm (figure )Tj 0.082 0.082 0.078 rg /T1_2 1 Tf 0 Tc 9.8 0 0 9.8 253.65 324.25 Tm (I)Tj 0.333 g 0.442 0 Td (. )Tj 0.216 0.216 0.212 rg /T1_0 1 Tf 0.05 Tc 10.2656 0 0 10.2 265.35 324.25 Tm (The )Tj 0.0086 Tc 10.2 0 0 10.2 54.13 313.21 Tm (excretion )Tj 0.05 Tc 11.1292 0 0 10.2 98.77 313.21 Tm (of )Tj 0.0286 Tc 10.2 0 0 10.2 112.7 313.21 Tm (cortiso)Tj 0.082 0.082 0.078 rg 0 Tc 2.919 0 Td (l )Tj 0.216 0.216 0.212 rg 0.0017 Tc 0.761 0 Td [(was )-293(significantly )]TJ 0.0172 Tc 7.718 0 Td (higher )Tj -0.0101 Tc 3.142 0 Td (\(76.3 )Tj 0.0042 Tc 9.8 0 0 9.8 54.12 302.16 Tm (\(25)Tj 0.4 0.404 0.392 rg 0 Tc 1.372 0 Td (-)Tj 0.216 0.216 0.212 rg -0.0006 Tc 0.593 0 Td (215\) )Tj 0.0223 Tc 10.2 0 0 10.2 95.03 302.16 Tm (nmol )Tj 0.0489 Tc 2.497 0 Td (per )Tj 0.141 0.141 0.137 rg 0.0385 Tc 1.635 0 Td (day\) )Tj 0.216 0.216 0.212 rg 0.0351 Tc 2.212 0 Td (during )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.05 Tc 10.3089 0 0 9.8 191.47 302.16 Tm (BUD )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.029 Tc 10.2 0 0 10.2 218.38 302.16 Tm (treatment )Tj 0.0392 Tc 4.376 0 Td (than )Tj 0.0257 Tc -20.478 -1.034 Td (during )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 10.2057 0 0 10.1 86.35 291.61 Tm (BOP )Tj EMC ET BT 0.333 g /T1_0 1 Tf 0 Tc 10.2 0 0 10.2 111.82 291.61 Tm (t)Tj 0.216 0.216 0.212 rg 0.0321 Tc 0.33 0 Td (reatment )Tj -0.0101 Tc 4.13 0 Td (\(53.7 )Tj 0.0186 Tc 9.8 0 0 9.8 182.28 291.61 Tm (\(6)Tj 0.333 g 0 Tc 0.834 0 Td (-)Tj 0.216 0.216 0.212 rg -0.0158 Tc 0.711 0 Td (118\) )Tj 0.0223 Tc 10.2 0 0 10.2 218.87 291.61 Tm (nmol )Tj 0.0018 Tc 2.638 0 Td (per )Tj 0.0228 Tc 1.682 0 Td (day\) )Tj 0.05 Tc 11.3737 0 0 10.2 54.11 280.56 Tm (\(p< )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0 Tc 9.8 0 0 9.8 72.86 280.56 Tm (0)Tj 0.333 g 0.529 0 Td (.)Tj 0.141 0.141 0.137 rg 0.0183 Tc 0.206 0 Td (01\). )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0252 Tc 10.2 0 0 10.2 98.79 280.56 Tm (This )Tj 0.0017 Tc 2.078 0 Td (was )Tj 0.0164 Tc 1.826 0 Td (also )Tj 0.0265 Tc 1.937 0 Td (the )Tj -0.0013 Tc 1.498 0 Td (case )Tj 0.141 0.141 0.137 rg 0.0427 Tc 1.928 0 Td (for )Tj 0.216 0.216 0.212 rg 0.0286 Tc 1.46 0 Td (cortiso)Tj 0.082 0.082 0.078 rg 0 Tc 2.919 0 Td (l )Tj 0.216 0.216 0.212 rg 0.0144 Tc 0.469 0 Td (excretion )Tj 0.0225 Tc -18.497 -1.081 Td (standardized )Tj 0.0192 Tc 5.838 0 Td (for )Tj 0.0146 Tc 1.742 0 Td (creatinine )Tj 0.0086 Tc 4.564 0 Td (excretion )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0105 Tc 9.8 0 0 9.8 222.12 269.53 Tm (\(10.2 )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 10.3398 0 0 10.2 248.05 269.53 Tm (and )Tj -0.0245 Tc 10.2 0 0 10.2 269.65 269.53 Tm (7.6 )Tj 0.0066 Tc -21.12 -1.082 Td (nmol )Tj 0.0253 Tc 2.579 0 Td (cortisol )Tj 0.0489 Tc 3.635 0 Td (per )Tj 0.0088 Tc 1.878 0 Td (mmol )Tj 0.0198 Tc 2.863 0 Td (creatinine )Tj 0.0489 Tc 4.576 0 Td (per )Tj 0.05 Tc 10.326 0 0 10.2 231.26 258.49 Tm (day )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf -0.0022 Tc 10.2 0 0 10.2 252.47 258.49 Tm (respec\255)Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf -0.0169 Tc 10.2 0 0 10.2 54.2228 247.933 Tm (tively; )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0291 Tc 10.2 0 0 10.2 84.0272 247.933 Tm (p>BDC 0.216 0.216 0.212 rg /T1_0 1 Tf -0.0061 Tc 9.8 0 0 9.8 262.7 236.89 Tm (1000 )Tj EMC ET BT /T1_0 1 Tf 0.037 Tc 10.2 0 0 10.2 53.66 225.37 Tm (and )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf -0.0061 Tc 9.8 0 0 9.8 75.02 225.37 Tm (1200 )Tj EMC /Suspect <>BDC 0.216 0.216 0.212 rg -0.035 Tc 9.7951 0 0 10.2 98.56 225.37 Tm (!!g )Tj EMC /Suspect <>BDC 0.05 Tc 10.4094 0 0 10.2 113.18 225.37 Tm (GCS )Tj EMC ET BT /T1_0 1 Tf 0.0489 Tc 10.2 0 0 10.2 138.74 225.37 Tm (per )Tj 0.0124 Tc 1.776 0 Td (day )Tj 0.0235 Tc 1.984 0 Td (than )Tj 0.082 0.082 0.078 rg 0 Tc 2.3 0 Td (i)Tj 0.216 0.216 0.212 rg 0.289 0 Td (n )Tj 0.0116 Tc 0.885 0 Td (child)Tj 0.082 0.082 0.078 rg 0 Tc 2.079 0 Td (r)Tj 0.216 0.216 0.212 rg 0.0179 Tc 0.367 0 Td (en )Tj 0.0262 Tc 1.468 0 Td (treated )Tj 0.0056 Tc -19.481 -1.036 Td (with )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0266 Tc 10.2 0 0 10.2 75.653 214.8028 Tm (800 )Tj EMC /Suspect <>BDC -0.035 Tc 9.7073 0 0 10.2 94.03 214.8 Tm (Jlg )Tj EMC ET BT /T1_0 1 Tf 0.0489 Tc 10.2 0 0 10.2 108.02 214.8 Tm (per )Tj 0.0034 Tc 1.682 0 Td (day. )Tj 0.141 0.141 0.137 rg 0.05 Tc 10.2656 0 0 10.2 63.27 203.76 Tm (The )Tj 0.0009 Tc 10.2 0 0 10.2 82.46 203.76 Tm (difference )Tj 0.216 0.216 0.212 rg -0.0079 Tc 4.284 0 Td (in )Tj 0.0186 Tc 1.033 0 Td (cortisol )Tj 0.0086 Tc 3.387 0 Td (excretion )Tj 0.0038 Tc 4.106 0 Td (between )Tj 0.0029 Tc 3.668 0 Td (the )Tj 0.0046 Tc 1.553 0 Td (two )Tj 0.0115 Tc -20.855 -1.034 Td (drugs )Tj -0.0218 Tc 2.738 0 Td (was )Tj 0.05 Tc 10.4827 0 0 10.2 101.27 193.21 Tm (not )Tj 0.0017 Tc 10.2 0 0 10.2 119.86 193.21 Tm (significantly )Tj -0.0013 Tc 5.418 0 Td (influenced )Tj -0.0022 Tc 4.668 0 Td (by )Tj 0.0265 Tc 1.409 0 Td (the )Tj -0.0051 Tc 1.733 0 Td (age )Tj 0.05 Tc 11.1292 0 0 10.2 273.01 193.21 Tm (of )Tj 0.0265 Tc 10.2 0 0 10.2 53.74 181.69 Tm (the )Tj -0.0001 Tc 1.545 0 Td (child )Tj -0.0079 Tc 2.355 0 Td (in )Tj 0.0265 Tc 1.088 0 Td (the )Tj 0.0475 Tc 9.8 0 0 9.8 120.42 181.69 Tm (22 )Tj 0.0118 Tc 10.2 0 0 10.2 133.34 181.69 Tm (chi)Tj 0.082 0.082 0.078 rg 0 Tc 1.272 0 Td (l)Tj 0.216 0.216 0.212 rg 0.0228 Tc 0.234 0 Td (dren )Tj 0.0353 Tc 2.174 0 Td (who )Tj -0.0058 Tc 2.071 0 Td (received )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.003 Tc 10.2 0 0 10.2 229.271 181.69 Tm (800 )Tj EMC /Suspect <>BDC 0.141 0.141 0.137 rg -0.035 Tc 9.7951 0 0 10.2 247.36 181.69 Tm (!!g )Tj EMC /Suspect <>BDC 0.0238 Tc 10.2 0 0 10.2 261.02 181.69 Tm (GCS )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0253 Tc 10.2 0 0 10.2 53.7764 171.133 Tm (per )Tj 0.0124 Tc 1.635 0 Td (day)Tj 0.333 g 0 Tc 1.542 0 Td (. )Tj 0.216 0.216 0.212 rg 0.05 Tc 10.2291 0 0 10.2 63.32 160.09 Tm (FEY )Tj /T1_2 1 Tf 0 Tc 6.2 0 0 6.2 84.28 157.69 Tm (1 )Tj /T1_0 1 Tf 0.0185 Tc 10.2 0 0 10.2 91.18 160.09 Tm (measured )Tj 0.05 Tc 10.7518 0 0 10.2 134.77 160.09 Tm (at )Tj 0.0265 Tc 10.2 0 0 10.2 146.38 160.09 Tm (the )Tj 0.0178 Tc 1.544 0 Td (end )Tj 0.05 Tc 10.5727 0 0 10.2 180.86 160.09 Tm (of )Tj 0.0087 Tc 10.2 0 0 10.2 192.37 160.09 Tm (each )Tj 0.0277 Tc 2.177 0 Td (period )Tj -0.0218 Tc 3.009 0 Td (was )Tj -0.0123 Tc 1.83 0 Td (2.35 )Tj -0.0194 Tc -20.618 -1.036 Td (\(0.9)Tj 0.333 g 0 Tc (-)Tj 0.216 0.216 0.212 rg -0.0134 Tc 2.118 0 Td (3.8\) )Tj ET BT /Suspect <>BDC /T1_3 1 Tf 0 Tc 10 0 0 10 94.39 149.52 Tm (I )Tj EMC /Suspect <>BDC /T1_0 1 Tf 0.0228 Tc 10.2 0 0 10.2 100.68 149.52 Tm (\(BOP\) )Tj EMC ET BT /T1_0 1 Tf 0.037 Tc 10.2 0 0 10.2 131.9022 149.52 Tm (and )Tj 0.0107 Tc 9.8 0 0 9.8 151.14 149.52 Tm (2.26 )Tj -0.0194 Tc 10.2 0 0 10.2 172.2 149.52 Tm (\(0.8)Tj 0.333 g 0 Tc 1.553 0 Td (-)Tj 0.216 0.216 0.212 rg -0.0134 Tc 0.612 0 Td (3.9\) )Tj ET BT /Suspect <>BDC /T1_3 1 Tf 0 Tc 10 0 0 10 213.43 149.52 Tm (I )Tj EMC /Suspect <>BDC /T1_0 1 Tf 0.0401 Tc 10.2 0 0 10.2 219.24 149.52 Tm (\(BUD\) )Tj EMC ET BT /T1_2 1 Tf -0.035 Tc 9.1388 0 0 9.7 252.8 149.52 Tm (\(Ns\). )Tj /T1_0 1 Tf 0.0219 Tc 10.2 0 0 10.2 63.27 138.49 Tm (There )Tj 0.0017 Tc 3.161 0 Td (was )Tj 0.0386 Tc 2.353 0 Td (no )Tj -0.0043 Tc 1.826 0 Td (difference )Tj 0.082 0.082 0.078 rg 0 Tc 4.802 0 Td (i)Tj 0.216 0.216 0.212 rg 0.289 0 Td (n )Tj 0.0208 Tc 1.262 0 Td (cortiso)Tj 0.082 0.082 0.078 rg 0 Tc 2.872 0 Td (l )Tj 0.216 0.216 0.212 rg 0.0203 Tc 0.986 0 Td (excretion )Tj -0.004 Tc -18.482 -1.083 Td (between )Tj 0.0029 Tc 3.621 0 Td (the )Tj 0.0282 Tc 1.463 0 Td (patients )Tj 0.0116 Tc 3.575 0 Td (using )Tj 0 Tc 2.437 0 Td (a )Tj 0.0107 Tc 0.707 0 Td (large )Tj 0.0135 Tc 2.266 0 Td (volume )Tj 0.0313 Tc 3.282 0 Td (spacer )Tj -0.0101 Tc 2.92 0 Td (\(62.7 )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0186 Tc 9.8 0 0 9.8 53.16 116.4 Tm (\(6)Tj 0.525 0.525 0.518 rg 0 Tc 0.834 0 Td (-)Tj 0.216 0.216 0.212 rg -0.0169 Tc 0.642 0 Td (204\) )Tj EMC ET BT /T1_0 1 Tf 0.0066 Tc 10.2 0 0 10.2 92.15 116.4 Tm (nmol )Tj 0.141 0.141 0.137 rg 0.0253 Tc 2.779 0 Td (per )Tj 0.0071 Tc 1.965 0 Td (day\) )Tj 0.216 0.216 0.212 rg 0.037 Tc 2.447 0 Td (and )Tj 0.0265 Tc 2.22 0 Td (the )Tj 0.0214 Tc 1.933 0 Td (patients )Tj 0.0116 Tc 3.904 0 Td (using )Tj 0 Tc 2.814 0 Td (a )Tj 0.0059 Tc -21.875 -1.082 Td (metered )Tj 0.0355 Tc 3.663 0 Td (dose )Tj 0.0438 Tc 2.308 0 Td (inha)Tj 0.082 0.082 0.078 rg 0 Tc 1.881 0 Td (l)Tj 0.216 0.216 0.212 rg 0.0438 Tc 0.233 0 Td (er )Tj 0.0267 Tc 1.225 0 Td (alone )Tj 0.0011 Tc 9.8 0 0 9.8 175.08 105.36 Tm (\(66. )Tj 0 Tc 10.2 0 0 10.2 191.41 105.36 Tm (7 )Tj 0.0042 Tc 9.8 0 0 9.8 200.04 105.36 Tm (\(13)Tj 0.525 0.525 0.518 rg 0 Tc 1.372 0 Td (-)Tj 0.216 0.216 0.212 rg 0.0157 Tc 0.593 0 Td (215\) )Tj 0.141 0.141 0.137 rg 0.0223 Tc 10.2 0 0 10.2 241.91 105.36 Tm (nmol )Tj 0.216 0.216 0.212 rg 0.0072 Tc 2.544 0 Td (pe)Tj 0.082 0.082 0.078 rg 0 Tc 0.985 0 Td (r )Tj 0.216 0.216 0.212 rg -0.0101 Tc -22.032 -1.035 Td (day\). )Tj 0.0288 Tc 0.991 -1.082 Td (In )Tj 0.0343 Tc 1.455 0 Td (four )Tj 0 Tc 2.354 0 Td (c)Tj 0.082 0.082 0.078 rg 0.479 0 Td (h)Tj 0.216 0.216 0.212 rg 0.0266 Tc 0.464 0 Td (ildren )Tj 0.0186 Tc 3.057 0 Td (cortisol )Tj 0.0144 Tc 3.717 0 Td (excretion )Tj 0.0185 Tc 4.479 0 Td (measured )Tj -0.0079 Tc 4.559 0 Td (in )Tj 0.0066 Tc -21.546 -1.082 Td (nmol )Tj 0.0253 Tc 2.356 0 Td (per )Tj 0.0359 Tc 1.588 0 Td (day )Tj 0.0017 Tc 1.797 0 Td (was )Tj 0.0078 Tc 1.837 0 Td (be)Tj 0.082 0.082 0.078 rg 0 Tc 0.978 0 Td (l)Tj 0.216 0.216 0.212 rg 0.0219 Tc 0.234 0 Td (ow )Tj 0.0029 Tc 1.561 0 Td (the )Tj 0.141 0.141 0.137 rg 0.0276 Tc 1.507 0 Td (normal )Tj 0.216 0.216 0.212 rg 0.0218 Tc 3.247 0 Td (range )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0391 Tc 10.2 0 0 10.2 233.6684 72.7302 Tm (in )Tj EMC ET BT 0.141 0.141 0.137 rg /T1_0 1 Tf 0.0265 Tc 10.2 0 0 10.2 244.766 72.7302 Tm (the )Tj ET BT /Suspect <>BDC 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0368 Tc 10.1 0 0 10.1 261.07 72.72 Tm (BDP )Tj EMC ET BT /T1_0 1 Tf 0.0206 Tc 10.2 0 0 10.2 307.22 728.41 Tm (period. )Tj 0.0252 Tc 3.33 0 Td (This )Tj 0.0017 Tc 2.267 0 Td (was )Tj -0.0029 Tc 1.917 0 Td (seen )Tj -0.0079 Tc 2.171 0 Td (in )Tj 0.0181 Tc 1.222 0 Td (one )Tj 0.0116 Tc 1.882 0 Td (child )Tj 0.0351 Tc 2.494 0 Td (during )Tj 0.0265 Tc 3.208 0 Td (the )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.05 Tc 10.3089 0 0 10.2 513.55 728.41 Tm (BUD )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0183 Tc 10.2 0 0 10.2 307.22 717.36 Tm (period)Tj 0.333 g 0 Tc 2.707 0 Td (. )Tj 0.216 0.216 0.212 rg 0.05 Tc 10.5034 0 0 10.2 340.73 717.36 Tm (In )Tj 0 Tc 10.2 0 0 10.2 353.74 717.36 Tm (t)Tj 0.082 0.082 0.078 rg 0.33 0 Td (h)Tj 0.216 0.216 0.212 rg 0.508 0 Td (e )Tj 0.0114 Tc 0.81 0 Td (remaining )Tj 0.0077 Tc 4.462 0 Td (cases )Tj 0.032 Tc 2.447 0 Td (cortisol )Tj 0.0203 Tc 3.528 0 Td (excretion )Tj 0.0017 Tc 4.245 0 Td (was )Tj 0.0173 Tc -20.894 -1.035 Td (within )Tj 0.0029 Tc 3.011 0 Td (the )Tj 0.0276 Tc 1.601 0 Td (normal )Tj 0.0051 Tc 3.341 0 Td (range. )Tj 0.05 Tc 10.943 0 0 10.2 316.85 695.76 Tm (No )Tj 0.0054 Tc 10.2 0 0 10.2 333.94 695.76 Tm (side )Tj -0.0088 Tc 1.932 0 Td (effects )Tj -0.0181 Tc 2.975 0 Td (were )Tj 0.0174 Tc 2.259 0 Td (reported. )Tj 0.141 0.141 0.137 rg -0.0097 Tc -0.757 -2.681 Td (Discussion )Tj 0.216 0.216 0.212 rg 0.0296 Tc -8.053 -1.6 Td (Comparison )Tj 0.05 Tc 11.1292 0 0 10.2 374.29 652.09 Tm (of )Tj 0.0001 Tc 10.2 0 0 10.2 387.26 652.09 Tm (clinical )Tj -0.0088 Tc 3.387 0 Td (effects )Tj 0.05 Tc 11.1292 0 0 10.2 453.01 652.09 Tm (of )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 10.2057 0 0 10.2 466.99 652.09 Tm (BDP )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.037 Tc 10.2 0 0 10.2 492.38 652.09 Tm (and )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 10.3089 0 0 10.2 513.55 652.09 Tm (BUD )Tj EMC ET BT /T1_0 1 Tf -0.0218 Tc 10.2 0 0 10.2 307.67 641.05 Tm (was )Tj 0.0455 Tc 2.212 0 Td (not )Tj 0.0265 Tc 2.07 0 Td (the )Tj 0.0417 Tc 1.929 0 Td (main )Tj 0.0309 Tc 2.78 0 Td (purpose )Tj 0.05 Tc 11.1292 0 0 10.2 440.05 641.05 Tm (of )Tj 10.8736 0 0 10.2 455.9 641.05 Tm (our )Tj 0.0207 Tc 10.2 0 0 10.2 477.94 641.05 Tm (study. )Tj 0.0486 Tc 3.251 0 Td (Other )Tj 0.0124 Tc -19.998 -1.036 Td (investigations )Tj 0.0001 Tc 6.077 0 Td (have )Tj 0.0237 Tc 2.249 0 Td (found )Tj 0.05 Tc 10.215 0 0 10.2 420.94 630.48 Tm (that )Tj 0 Tc 10.2 0 0 10.2 441.58 630.48 Tm (t)Tj 0.082 0.082 0.078 rg 0.33 0 Td (h)Tj 0.216 0.216 0.212 rg 0.0121 Tc 0.508 0 Td (ere )Tj 0.05 Tc 10.2757 0 0 10.2 466.46 630.48 Tm (are )Tj 0.0386 Tc 10.2 0 0 10.2 483.83 630.48 Tm (no )Tj 0.141 0.141 0.137 rg 0.0026 Tc 1.356 0 Td (clinically )Tj 0.216 0.216 0.212 rg 0.04 Tc -18.68 -1.082 Td (important )Tj -0.0052 Tc 4.657 0 Td (differences )Tj -0.0079 Tc 4.896 0 Td (in )Tj 0.0291 Tc 1.269 0 Td (anti-asthmatic )Tj 0.0234 Tc 6.553 0 Td (potency )Tj -0.0214 Tc 3.811 0 Td (be\255)Tj 0.0043 Tc -21.179 -1.081 Td (tween )Tj 0.021 Tc 2.815 0 Td (equivalent )Tj 0.0117 Tc 4.754 0 Td (doses )Tj 0.05 Tc 11.1292 0 0 10.2 412.69 608.41 Tm (of )Tj 0.0029 Tc 10.2 0 0 10.2 426.22 608.41 Tm (the )Tj 0.0046 Tc 1.741 0 Td (two )Tj 0.035 Tc 1.969 0 Td (drugs )Tj 0.141 0.141 0.137 rg -0.035 Tc 9.4414 0 0 10.1 492.73 608.41 Tm ([3)Tj 0.525 0.525 0.518 rg 0 Tc 10.1 0 0 10.1 501 608.41 Tm (-)Tj 0.216 0.216 0.212 rg -0.035 Tc 9.7128 0 0 10.1 506.78 608.41 Tm (7]. )Tj -0.0146 Tc 10.2 0 0 10.2 522.2 608.41 Tm (We )Tj 0.0257 Tc -21.135 -1.083 Td (concentrated )Tj 0.141 0.141 0.137 rg 0.0237 Tc 5.845 0 Td (upon )Tj 0.216 0.216 0.212 rg 0.021 Tc 2.483 0 Td (evaluating )Tj 0.0107 Tc 4.766 0 Td (possible )Tj 0.141 0.141 0.137 rg -0.0004 Tc 3.753 0 Td (differences )Tj 0.216 0.216 0.212 rg -0.0079 Tc 4.849 0 Td (in )Tj 0.0018 Tc -21.653 -1.035 Td (systemic )Tj 0 Tc 3.906 0 Td (s)Tj 0.082 0.082 0.078 rg 0.382 0 Td (i)Tj 0.216 0.216 0.212 rg 0.0072 Tc 0.28 0 Td (de )Tj -0.0167 Tc 1.364 0 Td (effects )Tj 0.0116 Tc 2.976 0 Td (between )Tj 0 Tc 3.856 0 Td (t)Tj 0.082 0.082 0.078 rg 0.33 0 Td (h)Tj 0.216 0.216 0.212 rg 0.508 0 Td (e )Tj 0.0046 Tc 0.903 0 Td (two )Tj 0.0156 Tc 1.969 0 Td (drugs. )Tj 0.05 Tc 10.9135 0 0 10.2 505.83 586.8 Tm (To )Tj 0.0265 Tc 10.2 0 0 10.2 523.18 586.8 Tm (the )Tj 0.0159 Tc -21.174 -1.082 Td (best )Tj 0.05 Tc 11.1292 0 0 10.2 326.77 575.76 Tm (of )Tj 0.0496 Tc 10.2 0 0 10.2 338.78 575.76 Tm (our )Tj 0.0049 Tc 1.749 0 Td (knowledge )Tj 0 Tc 4.753 0 Td (t)Tj 0.082 0.082 0.078 rg 0.283 0 Td (h)Tj 0.216 0.216 0.212 rg -0.035 Tc 10.1489 0 0 10.2 413.68 575.76 Tm (is )Tj 0.141 0.141 0.137 rg 0.0183 Tc 10.2 0 0 10.2 423.35 575.76 Tm (has )Tj 0.216 0.216 0.212 rg 0.0105 Tc 1.685 0 Td (only )Tj 0.0177 Tc 2.128 0 Td (been )Tj 0.05 Tc 10.6052 0 0 10.2 485.18 575.76 Tm (do)Tj 0.082 0.082 0.078 rg 0 Tc 10.2 0 0 10.2 496.79 575.76 Tm (n)Tj 0.216 0.216 0.212 rg 0.508 0 Td (e )Tj -0.035 Tc 9.9195 0 0 10.2 509.68 575.76 Tm (in )Tj 0.0416 Tc 10.2 0 0 10.2 520.7 575.76 Tm (one )Tj 0.0177 Tc -20.989 -1.081 Td (earlier )Tj 0.0413 Tc 2.868 0 Td (study )Tj 0.0391 Tc 2.547 0 Td (in )Tj 0.0193 Tc 1.033 0 Td (children )Tj 0 Tc 3.656 0 Td ([ )Tj 0.141 0.141 0.137 rg 0.392 0 Td (l )Tj 0.216 0.216 0.212 rg -0.03 Tc 0.327 0 Td (]. )Tj 0.05 Tc 10.2656 0 0 10.2 425.19 564.73 Tm (The )Tj 0.0066 Tc 10.2 0 0 10.2 444.37 564.73 Tm (findings )Tj 0.05 Tc 11.1292 0 0 10.2 481.33 564.73 Tm (of )Tj 10.215 0 0 10.2 492.94 564.73 Tm (that )Tj 0.0295 Tc 10.2 0 0 10.2 512.5 564.73 Tm (study )Tj 0.0151 Tc -20.135 -1.083 Td (indicated )Tj 0 Tc 4.092 0 Td (a )Tj 0.141 0.141 0.137 rg -0.0043 Tc 0.8 0 Td (difference )Tj -0.0079 Tc 4.331 0 Td (in )Tj 0.216 0.216 0.212 rg 0.0085 Tc 1.076 0 Td (systemic )Tj 0.0054 Tc 3.859 0 Td (side )Tj -0.0088 Tc 1.932 0 Td (effects )Tj 0.0116 Tc 2.929 0 Td (between )Tj 0.0265 Tc -19.015 -1.035 Td (the )Tj 0.0281 Tc 1.882 0 Td (two )Tj 0.0232 Tc 2.157 0 Td (drugs )Tj 0.05 Tc 10.6555 0 0 10.2 378.15 543.12 Tm (in )Tj 0.0297 Tc 10.2 0 0 10.2 392.53 543.12 Tm (favour )Tj 0.05 Tc 11.1292 0 0 10.2 427.09 543.12 Tm (of )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 10.2235 0 0 10.2 442.51 543.12 Tm (BUD. )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0207 Tc 10.2 0 0 10.2 474.67 543.12 Tm (However, )Tj 0.141 0.141 0.137 rg 0.0265 Tc 4.709 0 Td (the )Tj 0.216 0.216 0.212 rg 0.0009 Tc -21.184 -1.081 Td (difference )Tj -0.0161 Tc 4.846 0 Td (failed )Tj 0.0253 Tc 3.115 0 Td (to )Tj 0.141 0.141 0.137 rg 0.0125 Tc 1.601 0 Td (reach )Tj 0.216 0.216 0.212 rg 0.0209 Tc 3.046 0 Td (statistical )Tj 0.0043 Tc 4.753 0 Td (significance)Tj 0.333 g 0 Tc 4.892 0 Td (, )Tj 0.216 0.216 0.212 rg 0.0247 Tc -22.194 -1.082 Td (perhaps )Tj 0.0003 Tc 3.764 0 Td (because )Tj 0.0105 Tc 3.66 0 Td (only )Tj 0 Tc 2.259 0 Td (a )Tj 0.0096 Tc 0.942 0 Td (limited )Tj 0.0489 Tc 3.396 0 Td (number )Tj 0.05 Tc 11.1292 0 0 10.2 488.53 521.05 Tm (of )Tj 0.0282 Tc 10.2 0 0 10.2 502.1 521.05 Tm (patients )Tj -0.0218 Tc -19.109 -1.035 Td (was )Tj -0.0056 Tc 1.976 0 Td (receiving )Tj 0.141 0.141 0.137 rg 0.0489 Tc 10.1 0 0 10.1 370.03 510.49 Tm (BUD )Tj 0.216 0.216 0.212 rg /T1_2 1 Tf 0.05 Tc 10.8886 0 0 9.4 396.77 510.49 Tm (\(n= )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf -0.0141 Tc 9.8 0 0 9.8 416.3 510.49 Tm (10\). )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.05 Tc 10.5034 0 0 10.1 435.77 510.49 Tm (In )Tj 10.2 0 0 10.2 449.74 510.49 Tm (the )Tj 0.0305 Tc 1.745 0 Td (present )Tj 0.05 Tc 10.4453 0 0 10.2 502.89 510.49 Tm (stu)Tj 0.082 0.082 0.078 rg 0 Tc 10.2 0 0 10.2 515.9 510.49 Tm (d)Tj 0.216 0.216 0.212 rg 0.574 0 Td [(y )-135(a )]TJ 0.0107 Tc -21.043 -1.083 Td (large )Tj 0.141 0.141 0.137 rg 0.0301 Tc 2.596 0 Td (number )Tj 0.216 0.216 0.212 rg 0.05 Tc 11.1292 0 0 10.2 371.89 499.44 Tm (of )Tj 0.0126 Tc 10.2 0 0 10.2 386.3 499.44 Tm (children )Tj -0.0058 Tc 3.962 0 Td (received )Tj 0.141 0.141 0.137 rg 0.05 Tc 10.264 0 0 10.2 467.53 499.44 Tm (both )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 10.2057 0 0 10.1 493.39 499.44 Tm (BDP )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 10.3398 0 0 10.2 519.73 499.44 Tm (and )Tj 0.141 0.141 0.137 rg 10.3089 0 0 10.2 307.15 488.41 Tm (BUD )Tj 0.216 0.216 0.212 rg 0.037 Tc 10.2 0 0 10.2 337.82 488.41 Tm (and )Tj 0.0311 Tc 2.363 0 Td (under )Tj 0.0145 Tc 3.198 0 Td (those )Tj 0.0317 Tc 2.957 0 Td (condit)Tj 0.082 0.082 0.078 rg 0 Tc 2.684 0 Td (i)Tj 0.216 0.216 0.212 rg 0.0216 Tc 0.28 0 Td (ons )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.05 Tc 10.2057 0 0 10.2 478.03 488.41 Tm (BOP )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 10.2918 0 0 10.2 506.87 488.41 Tm (had )Tj 0 Tc 10.2 0 0 10.2 530.78 488.41 Tm (a )Tj 0.0017 Tc -21.98 -1.036 Td (significantly )Tj 0.0078 Tc 5.613 0 Td (higher )Tj 0.0297 Tc 3.144 0 Td (adrenal )Tj 0.0162 Tc 3.667 0 Td (suppressive )Tj -0.0081 Tc 5.368 0 Td (effect )Tj 0.05 Tc 10.2803 0 0 10.2 516.45 477.84 Tm (than )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.0205 Tc 10.2 0 0 10.2 307.15 466.81 Tm (BUD. )Tj EMC /Suspect <>BDC 0.216 0.216 0.212 rg 0 Tc 3.092 0 Td (S)Tj 0.082 0.082 0.078 rg 0.575 0 Td (i)Tj 0.216 0.216 0.212 rg -0.009 Tc 0.289 0 Td (nce )Tj EMC ET BT 0.141 0.141 0.137 rg /T1_0 1 Tf 0.0265 Tc 10.2 0 0 10.2 368.1358 466.81 Tm (the )Tj 0.216 0.216 0.212 rg 0.0208 Tc 1.875 0 Td (cortiso)Tj 0.082 0.082 0.078 rg 0 Tc 2.919 0 Td (l )Tj 0.216 0.216 0.212 rg 0.0144 Tc 0.845 0 Td (excretion )Tj 0.05 Tc 11.1292 0 0 10.2 471.73 466.81 Tm (of )Tj 0.141 0.141 0.137 rg 0.044 Tc 10.2 0 0 10.2 487.18 466.81 Tm (most )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 10.2057 0 0 10.2 514.99 466.81 Tm (BOP )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0118 Tc 10.2 0 0 10.2 306.14 455.76 Tm (chi)Tj 0.082 0.082 0.078 rg 0 Tc 1.319 0 Td (l)Tj 0.216 0.216 0.212 rg 0.0228 Tc 0.234 0 Td (dren )Tj 0.0017 Tc 2.456 0 Td (was )Tj 0.0079 Tc 2.118 0 Td (within )Tj 0.0029 Tc 3.246 0 Td (the )Tj 0.037 Tc 1.789 0 Td (normal )Tj 0.0218 Tc 3.624 0 Td (range )Tj 0.0265 Tc 2.917 0 Td (the )Tj 0 Tc 1.827 0 Td (c)Tj 0.082 0.082 0.078 rg 0.425 0 Td (l)Tj 0.216 0.216 0.212 rg 0.0249 Tc 0.236 0 Td (inica)Tj 0.082 0.082 0.078 rg 0 Tc 2.07 0 Td (l )Tj 0.216 0.216 0.212 rg 0.0307 Tc -22.211 -1.082 Td (importance)Tj 0.333 g 0 Tc 4.745 0 Td (, )Tj 0.216 0.216 0.212 rg 0.05 Tc 11.1828 0 0 10.2 360.87 444.72 Tm (if )Tj 0.0197 Tc 10.2 0 0 10.2 369.98 444.72 Tm (any, )Tj 0.05 Tc 11.1292 0 0 10.2 391.57 444.72 Tm (of )Tj 0.0061 Tc 10.2 0 0 10.2 403.66 444.72 Tm (this )Tj 0.0183 Tc 1.789 0 Td (has )Tj 0.0034 Tc 1.741 0 Td (yet )Tj 0.05 Tc 10.4772 0 0 10.2 455.49 444.72 Tm (to )Tj 0.0078 Tc 10.2 0 0 10.2 468.01 444.72 Tm (be )Tj 0.0221 Tc 1.212 0 Td (elucidated )Tj 0.141 0.141 0.137 rg 0.0391 Tc 4.615 0 Td (in )Tj 0.216 0.216 0.212 rg 0.0157 Tc -21.637 -1.081 Td (prospective )Tj 0.141 0.141 0.137 rg 0.0212 Tc 5.166 0 Td (long-term )Tj 0.216 0.216 0.212 rg 0.0071 Tc 4.517 0 Td (clinica)Tj 0.082 0.082 0.078 rg 0 Tc 2.73 0 Td (l )Tj 0.216 0.216 0.212 rg 0.0154 Tc 0.713 0 Td (trials)Tj 0.333 g 0 Tc 2.104 0 Td (, )Tj 0.216 0.216 0.212 rg 0.712 0 Td (a)Tj 0.082 0.082 0.078 rg 0.519 0 Td (l)Tj 0.216 0.216 0.212 rg 0.0304 Tc 0.23 0 Td (so )Tj 0.0262 Tc 1.368 0 Td (evaluating )Tj 0.0448 Tc -18.07 -1.036 Td (other )Tj 0.0266 Tc 2.459 0 Td (parameters )Tj 0.0095 Tc 4.878 0 Td (such )Tj 0.0261 Tc 2.122 0 Td (as )Tj 0.0221 Tc 1.083 0 Td (growth, )Tj 0.141 0.141 0.137 rg 0.03 Tc 3.539 0 Td (bone )Tj 0.216 0.216 0.212 rg 0.0203 Tc 2.303 0 Td (mineralizatio)Tj 0.082 0.082 0.078 rg 0 Tc 5.554 0 Td (n )Tj 0.216 0.216 0.212 rg 0.05 Tc 10.3398 0 0 10.2 306.61 412.09 Tm (and )Tj 0.01 Tc 10.2 0 0 10.2 325.82 412.09 Tm (calcium )Tj 0.0086 Tc 3.575 0 Td (excretion )Tj 0.0391 Tc 4.144 0 Td (in )Tj 0.0265 Tc 1.182 0 Td (the )Tj 0.141 0.141 0.137 rg 0.0101 Tc 1.649 0 Td (urine. )Tj ET BT /Suspect <>BDC 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0138 Tc 10.2 0 0 10.2 461.5616 412.09 Tm (So )Tj EMC ET BT /T1_0 1 Tf 0.0477 Tc 10.2 0 0 10.2 476.0456 412.09 Tm (far )Tj 0.141 0.141 0.137 rg 0.0386 Tc 1.563 0 Td (no )Tj 0.216 0.216 0.212 rg 0.0201 Tc 1.399 0 Td (studies )Tj 0.141 0.141 0.137 rg 0.0315 Tc -19.611 -1.082 Td (have )Tj 0.021 Tc 2.205 0 Td (indicated )Tj 0.216 0.216 0.212 rg 0.037 Tc 4.045 0 Td (any )Tj 0.0135 Tc 1.741 0 Td (clinical )Tj 0.0085 Tc 3.196 0 Td (systemic )Tj 0.0013 Tc 3.721 0 Td (effect )Tj 0.05 Tc 11.1292 0 0 10.2 483.73 401.05 Tm (of )Tj 0.141 0.141 0.137 rg 0.0207 Tc 10.2 0 0 10.2 494.87 401.05 Tm (high )Tj 0.0355 Tc 2.062 0 Td (dose )Tj 0.0225 Tc -20.516 -1.083 Td (inhaled )Tj ET BT /Suspect <>BDC 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0266 Tc 10.2 0 0 10.2 340.697 390.0034 Tm (GCS, )Tj EMC ET BT /T1_0 1 Tf 0.0372 Tc 10.2 0 0 10.2 366.4724 390.0034 Tm (just )Tj 0.141 0.141 0.137 rg 0.0261 Tc 1.802 0 Td (as )Tj 0.216 0.216 0.212 rg 0.0282 Tc 1.141 0 Td (patients )Tj 0.05 Tc 10.7226 0 0 10.2 432.86 390 Tm (on )Tj 0.0252 Tc 10.2 0 0 10.2 446.74 390 Tm (such )Tj 0.0408 Tc 2.176 0 Td (treatment )Tj 0.0213 Tc 4.369 0 Td (often )Tj 0.0263 Tc -20.286 -1.081 Td (show )Tj 0.0216 Tc 2.871 0 Td (steroid )Tj -0.0005 Tc 3.589 0 Td (wit)Tj 0.082 0.082 0.078 rg 0 Tc 1.318 0 Td (h)Tj 0.216 0.216 0.212 rg 0.0391 Tc 0.509 0 Td (drawa)Tj 0.082 0.082 0.078 rg 0 Tc 2.589 0 Td (l )Tj 0.216 0.216 0.212 rg 0.0284 Tc 1.03 0 Td (symptoms )Tj 0.05 Tc 10.3398 0 0 10.2 479.41 378.97 Tm (and )Tj 0.141 0.141 0.137 rg 0.0323 Tc 10.2 0 0 10.2 503.02 378.97 Tm (marked )Tj 0.216 0.216 0.212 rg 0.0195 Tc -19.253 -1.082 Td (improvement )Tj 0.0391 Tc 6.212 0 Td (in )Tj 0.0218 Tc 1.504 0 Td (adrenal )Tj 0.019 Tc 3.811 0 Td (function )Tj 0.0171 Tc 4.198 0 Td (when )Tj 0.0078 Tc 2.964 0 Td (they )Tj 0.0313 Tc 2.439 0 Td (are )Tj 0.0025 Tc -21.121 -1.082 Td (weaned )Tj 0.039 Tc 3.426 0 Td (off )Tj 0.05 Tc 10.2699 0 0 10.2 356.54 356.89 Tm (oral )Tj 0.0168 Tc 10.2 0 0 10.2 377.14 356.89 Tm (steroids )Tj 0.141 0.141 0.137 rg 0.0279 Tc 9.8 0 0 9.8 413.52 356.89 Tm ([8-1 )Tj ET BT /Suspect <>BDC 0.216 0.216 0.212 rg /T1_0 1 Tf -0.035 Tc 7.9449 0 0 9.8 431.92 356.89 Tm (OJ. )Tj EMC ET BT /T1_0 1 Tf 0.0221 Tc 10.2 0 0 10.2 316.75 346.33 Tm (Measurement )Tj 0.05 Tc 11.1292 0 0 10.2 378.13 346.33 Tm (of )Tj -0.0027 Tc 10.2 0 0 10.2 390.73 346.33 Tm (baseli)Tj 0.082 0.082 0.078 rg 0 Tc 2.351 0 Td (n)Tj 0.216 0.216 0.212 rg 0.508 0 Td (e )Tj 0.0186 Tc 0.754 0 Td (cortisol )Tj 0.0203 Tc 3.481 0 Td (excretion )Tj 0.0361 Tc 4.188 0 Td (from )Tj 0 Tc 2.401 0 Td (a )Tj 0.0183 Tc -21.918 -1.083 Td (period )Tj 0.0331 Tc 3.009 0 Td (without )Tj 0.141 0.141 0.137 rg 0.0147 Tc 3.617 0 Td (inhaled )Tj ET BT /Suspect <>BDC 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0473 Tc 10.2 0 0 10.2 409.3348 335.2834 Tm (GCS )Tj EMC ET BT /T1_0 1 Tf 0.0017 Tc 10.2 0 0 10.2 434.386 335.2834 Tm (was )Tj 0.141 0.141 0.137 rg 0.05 Tc 10.4827 0 0 10.2 454.07 335.28 Tm (not )Tj 0.216 0.216 0.212 rg 0.0179 Tc 10.2 0 0 10.2 472.34 335.28 Tm (possib)Tj 0.082 0.082 0.078 rg 0 Tc 2.672 0 Td (l)Tj 0.216 0.216 0.212 rg 0.233 0 Td (e )Tj -0.0079 Tc 0.803 0 Td (in )Tj 0.0029 Tc 1.229 0 Td (the )Tj 0.0214 Tc -21.173 -1.081 Td (patients )Tj 0.0173 Tc 3.937 0 Td (studied )Tj 0.05 Tc 10.3398 0 0 10.2 384.85 324.25 Tm (and )Tj 0.0203 Tc 10.2 0 0 10.2 407.98 324.25 Tm (therefore )Tj 0.05 Tc 4.471 0 Td (the )Tj 0.0264 Tc 2.024 0 Td (magnitude )Tj 0.05 Tc 11.1292 0 0 10.2 526.45 324.25 Tm (of )Tj 0.0009 Tc 10.2 0 0 10.2 306.1 313.21 Tm (syste)Tj 0.082 0.082 0.078 rg 0 Tc 2.035 0 Td (m)Tj 0.216 0.216 0.212 rg 0.002 Tc 0.794 0 Td (ic )Tj 0.0108 Tc 1.222 0 Td (activity )Tj 0.05 Tc 11.1292 0 0 10.2 384.37 313.21 Tm (of )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 10.3089 0 0 10.2 398.83 313.21 Tm (BUD )Tj EMC ET BT /T1_0 1 Tf 0.0382 Tc 10.2 0 0 10.2 426.62 313.21 Tm (could )Tj 0.05 Tc 10.4827 0 0 10.2 456.47 313.21 Tm (not )Tj 0.0078 Tc 10.2 0 0 10.2 476.65 313.21 Tm (be )Tj 0.0199 Tc 1.447 0 Td (evaluated. )Tj 0.014 Tc -18.159 -1.035 Td (However, )Tj 0 Tc 4.654 0 Td (a )Tj 0.0294 Tc 1.094 0 Td (pharmacokinetic )Tj 0.0181 Tc 7.655 0 Td (st)Tj 0.082 0.082 0.078 rg 0 Tc 0.72 0 Td (u)Tj 0.216 0.216 0.212 rg 0.0443 Tc 0.508 0 Td (dy )Tj 0 Tc 1.656 0 Td (w)Tj 0.082 0.082 0.078 rg 0.746 0 Td (i)Tj 0.216 0.216 0.212 rg 0.0253 Tc 0.288 0 Td (th )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 10.3089 0 0 10.2 498.19 302.65 Tm (BUD )Tj EMC ET BT /T1_0 1 Tf -0.0079 Tc 10.2 0 0 10.2 526.96 302.65 Tm (in )Tj 0.0193 Tc -21.649 -1.082 Td (children )Tj 0.021 Tc 3.673 0 Td (indicated )Tj 0.05 Tc 10.215 0 0 10.2 385.42 291.61 Tm (that )Tj 0.0265 Tc 10.2 0 0 10.2 405.1 291.61 Tm (the )Tj 0.0024 Tc 1.554 0 Td (risk )Tj 0.05 Tc 11.1292 0 0 10.2 439.57 291.61 Tm (of )Tj 0.0085 Tc 10.2 0 0 10.2 451.06 291.61 Tm (systemic )Tj 0.0054 Tc 3.765 0 Td (side )Tj -0.0088 Tc 1.885 0 Td (effects )Tj 0.0212 Tc -19.849 -1.083 Td (with )Tj 0.0061 Tc 2.117 0 Td (this )Tj 0.05 Tc 10.2128 0 0 10.2 345.5 280.56 Tm (drug )Tj -0.035 Tc 10.1489 0 0 10.2 368.56 280.56 Tm (is )Tj 0.141 0.141 0.137 rg -0.0132 Tc 10.2 0 0 10.2 378.15 280.56 Tm (low, )Tj 0.216 0.216 0.212 rg -0.0008 Tc 2.019 0 Td (since )Tj 0.141 0.141 0.137 rg 0.0269 Tc 2.312 0 Td (it )Tj 0.216 0.216 0.212 rg 0.0017 Tc 0.854 0 Td (was )Tj 0.0225 Tc 1.882 0 Td (rapidly )Tj 0.016 Tc 3.246 0 Td (metabolized )Tj 0.0304 Tc -17.376 -1.081 Td (so )Tj 0.05 Tc 10.215 0 0 10.2 319.66 269.53 Tm (that )Tj 0.0311 Tc 10.2 0 0 10.2 340.18 269.53 Tm (serum )Tj 0.141 0.141 0.137 rg -0.0204 Tc 2.923 0 Td (levels )Tj 0.05 Tc 11.1292 0 0 10.2 396.85 269.53 Tm (of )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0382 Tc 10.2 0 0 10.2 409.87 269.53 Tm (BUD )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf -0.0024 Tc 10.2 0 0 10.2 436.3084 269.53 Tm (were )Tj 0.0027 Tc 2.344 0 Td (always )Tj 0.0037 Tc 3.211 0 Td (below )Tj 0.0265 Tc 2.868 0 Td (the )Tj 0.0201 Tc -21.184 -1.082 Td (detection )Tj 0.0149 Tc 4.472 0 Td (limit )Tj 0.05 Tc 11.1292 0 0 10.2 378.13 258.49 Tm (of )Tj 0.0265 Tc 10.2 0 0 10.2 393.1 258.49 Tm (the )Tj 0.0147 Tc 1.922 0 Td (assay )Tj 0.141 0.141 0.137 rg 0.05 Tc 10.8345 0 0 10.4 442.03 258.49 Tm (4-8 )Tj 0.0455 Tc 10.2 0 0 10.2 464.63 258.49 Tm (hours )Tj 0.216 0.216 0.212 rg 0.0396 Tc 3.003 0 Td (after )Tj 0.0265 Tc 2.643 0 Td (the )Tj 0.0286 Tc -21.182 -1.035 Td (inhalation )Tj 0.05 Tc 11.1292 0 0 10.2 353.17 247.93 Tm (of )Tj 0 Tc 10.1 0 0 10.1 366.37 247.93 Tm (1 )Tj -0.002 Tc 10.2 0 0 10.2 373.9 247.93 Tm (mg )Tj 0.141 0.141 0.137 rg 0.05 Tc 10.3089 0 0 10.1 390.67 247.93 Tm (BUD )Tj 0.216 0.216 0.212 rg 0 Tc 10.1 0 0 10.1 416.88 247.93 Tm ([)Tj 0.082 0.082 0.078 rg 0.369 0 Td (1)Tj 0.216 0.216 0.212 rg -0.035 Tc 9.1759 0 0 10.1 425.44 247.93 Tm (1]. )Tj 0.141 0.141 0.137 rg 0.05 Tc 10.2656 0 0 10.2 315.75 236.89 Tm (The )Tj 0.216 0.216 0.212 rg 0.0482 Tc 10.2 0 0 10.2 340.22 236.89 Tm (asthma )Tj 0.0284 Tc 3.808 0 Td (symptoms )Tj 0.05 Tc 11.1292 0 0 10.2 430.93 236.89 Tm (of )Tj 0.0458 Tc 10.2 0 0 10.2 447.34 236.89 Tm (many )Tj 0.0193 Tc 3.098 0 Td (children )Tj 0.0313 Tc 4.235 0 Td (are )Tj 0.0487 Tc -21.224 -1.082 Td (contro)Tj 0.082 0.082 0.078 rg -0.035 Tc 9.5286 0 0 10.2 334.48 225.85 Tm (ll)Tj 0.216 0.216 0.212 rg 0.0179 Tc 10.2 0 0 10.2 339.73 225.85 Tm (ed )Tj -0.0022 Tc 1.282 0 Td (by )Tj 0.082 0.082 0.078 rg 0 Tc 1.308 0 Td (l)Tj 0.216 0.216 0.212 rg 0.0153 Tc 0.281 0 Td (ower )Tj 0.0117 Tc 2.353 0 Td (doses )Tj 0.05 Tc 11.1292 0 0 10.2 419.41 225.85 Tm (of )Tj 0.0438 Tc 10.2 0 0 10.2 430.96 225.85 Tm (inha)Tj 0.082 0.082 0.078 rg 0 Tc 1.881 0 Td (l)Tj 0.216 0.216 0.212 rg 0.0179 Tc 0.233 0 Td (ed )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0473 Tc 10.2 0 0 10.2 465.9766 225.85 Tm (GCS )Tj EMC ET BT /T1_0 1 Tf 0.0392 Tc 10.2 0 0 10.2 490.0588 225.85 Tm (than )Tj 0.0263 Tc 2.212 0 Td (those )Tj 0.017 Tc -20.28 -1.083 Td (used )Tj 0.0391 Tc 2.251 0 Td (in )Tj 0.0265 Tc 1.229 0 Td (the )Tj 0.0305 Tc 1.604 0 Td (present )Tj 0.0295 Tc 3.42 0 Td (study)Tj 0.082 0.082 0.078 rg 0 Tc 2.299 0 Td (. )Tj ET BT /Suspect <>BDC 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0129 Tc 10.2 0 0 10.2 421.7392 214.8034 Tm (Systemic )Tj EMC ET BT /T1_0 1 Tf 0.0108 Tc 10.2 0 0 10.2 463.5898 214.8034 Tm (activity )Tj 0.05 Tc 11.6856 0 0 10.2 498.61 214.8 Tm (of )Tj 0.0233 Tc 10.2 0 0 10.2 511.11 214.8 Tm (lower )Tj 0.0117 Tc -20.142 -1.082 Td (doses )Tj 0.05 Tc 11.1292 0 0 10.2 336.37 203.76 Tm (of )Tj 0.0265 Tc 10.2 0 0 10.2 352.3 203.76 Tm (the )Tj 0.0281 Tc 1.976 0 Td (two )Tj 0.141 0.141 0.137 rg 0.035 Tc 2.251 0 Td (drugs )Tj 0.216 0.216 0.212 rg 0.0271 Tc 3.055 0 Td (should )Tj 0.0164 Tc 3.533 0 Td (also )Tj /T1_2 1 Tf -0.035 Tc 9.1853 0 0 10.2 487.02 203.76 Tm (be )Tj /T1_0 1 Tf 0.0252 Tc 10.2 0 0 10.2 503.86 203.76 Tm (studied )Tj 0.0164 Tc -19.376 -1.034 Td (therefore, )Tj -0.0079 Tc 4.324 0 Td (in )Tj 0.0426 Tc 1.08 0 Td (order )Tj 0.0253 Tc 2.549 0 Td (to )Tj -0.008 Tc 1.122 0 Td (define )Tj 0.023 Tc 2.784 0 Td (more )Tj 0.0213 Tc 2.392 0 Td (accurately )Tj 0.05 Tc 10.7518 0 0 10.2 498.61 193.21 Tm (at )Tj 0.0024 Tc 10.2 0 0 10.2 509.75 193.21 Tm (which )Tj 0.0198 Tc -20.009 -1.083 Td (dose )Tj 0 Tc 2.541 0 Td (a )Tj 0.0092 Tc 1.173 0 Td (significant )Tj 0.0053 Tc 4.941 0 Td (system)Tj 0.082 0.082 0.078 rg 0 Tc 2.829 0 Td (i)Tj 0.216 0.216 0.212 rg 0.233 0 Td (c )Tj -0.0081 Tc 1.081 0 Td (effect )Tj 0.05 Tc 10.5727 0 0 10.2 465.98 182.16 Tm (or )Tj 0 Tc 10.2 0 0 10.2 481.82 182.16 Tm (a )Tj -0.0104 Tc 1.129 0 Td (diffe)Tj 0.082 0.082 0.078 rg 0 Tc 1.891 0 Td (r)Tj 0.216 0.216 0.212 rg 0.0087 Tc 0.367 0 Td (ence )Tj 0.141 0.141 0.137 rg 0.0038 Tc -20.6 -1.081 Td (between )Tj 0.216 0.216 0.212 rg 0.0265 Tc 3.997 0 Td (the )Tj 0.0046 Tc 1.929 0 Td (two )Tj 0.035 Tc 2.11 0 Td (drugs )Tj -0.0079 Tc 2.967 0 Td (in )Tj 0.0085 Tc 1.406 0 Td (systemic )Tj -0.0081 Tc 4.144 0 Td (effect )Tj 0.0464 Tc 2.825 0 Td (can )Tj 0.0078 Tc 2.128 0 Td (be )Tj 0.0129 Tc -21.564 -1.082 Td (detected. )Tj 0.0321 Tc 8.987 -2.635 Td (Co)Tj 0.082 0.082 0.078 rg -0.0232 Tc 1.186 0 Td (nclu)Tj 0.216 0.216 0.212 rg -0.0057 Tc 1.634 0 Td (sio)Tj 0.082 0.082 0.078 rg 0 Tc 1.189 0 Td (n )Tj 0.216 0.216 0.212 rg 0.0276 Tc -12.004 -1.648 Td (High )Tj 0.0198 Tc 2.63 0 Td (dose )Tj 0.0225 Tc 2.449 0 Td (inhaled )Tj 0.0265 Tc 3.629 0 Td (therapy )Tj 0.0212 Tc 3.719 0 Td (with )Tj ET BT /Suspect <>BDC 0.141 0.141 0.137 rg /T1_0 1 Tf 0.05 Tc 10.2057 0 0 10.2 467.47 116.4 Tm (BOP )Tj EMC ET BT 0.216 0.216 0.212 rg /T1_0 1 Tf 0.0124 Tc 10.2 0 0 10.2 493.91 116.4 Tm (results )Tj -0.0079 Tc 3.24 0 Td (in )Tj 0.0056 Tc -21.7 -1.082 Td (significantly )Tj 0.0115 Tc 5.417 0 Td (lower )Tj 0 Tc 2.691 0 Td (u)Tj 0.082 0.082 0.078 rg 0.564 0 Td (r)Tj 0.216 0.216 0.212 rg 0.0098 Tc 0.37 0 Td (ine )Tj 0.0286 Tc 1.551 0 Td (cortiso)Tj 0.082 0.082 0.078 rg 0 Tc 2.919 0 Td (l )Tj 0.216 0.216 0.212 rg 0.0203 Tc 0.61 0 Td (excretion )Tj 0.05 Tc 10.2803 0 0 10.2 492.93 105.36 Tm (than )Tj 0.0207 Tc 10.2 0 0 10.2 515.99 105.36 Tm (high )Tj 0.141 0.141 0.137 rg 0.0355 Tc -20.668 -1.035 Td (dose )Tj 0.0147 Tc 2.543 0 Td (inhaled )Tj 0.216 0.216 0.212 rg 0 Tc 3.676 0 Td (t)Tj 0.082 0.082 0.078 rg 0.33 0 Td (h)Tj 0.216 0.216 0.212 rg 0.0267 Tc 0.508 0 Td (erapy )Tj 0.0212 Tc 2.927 0 Td (with )Tj 0.141 0.141 0.137 rg 0.05 Tc 10.3089 0 0 10.1 431.95 94.8 Tm (BUD )Tj 0.082 0.082 0.078 rg -0.0079 Tc 10.2 0 0 10.2 461.2 94.8 Tm (in )Tj 0.216 0.216 0.212 rg 0.0118 Tc 1.363 0 Td (chi)Tj 0.082 0.082 0.078 rg -0.0088 Tc 1.272 0 Td (ld)Tj 0.216 0.216 0.212 rg 0.021 Tc 0.808 0 Td (ren )Tj -0.0005 Tc 1.929 0 Td (wit)Tj 0.082 0.082 0.078 rg 0 Tc 1.318 0 Td (h )Tj 0.216 0.216 0.212 rg 0.0254 Tc -21.938 -1.082 Td (asthma; )Tj 0.0265 Tc 3.914 0 Td (the )Tj 0.141 0.141 0.137 rg -0.0043 Tc 1.875 0 Td (difference )Tj 0.216 0.216 0.212 rg 0.0121 Tc 4.623 0 Td (being )Tj 0.0387 Tc 2.868 0 Td (more )Tj 0.141 0.141 0.137 rg 0.0361 Tc 2.733 0 Td (pronounced )Tj 0.0391 Tc 5.637 0 Td (in )Tj 0.216 0.216 0.212 rg 0 Tc -21.696 -1.082 Td (c)Tj 0.082 0.082 0.078 rg 0.479 0 Td (h)Tj 0.216 0.216 0.212 rg 0.0078 Tc 0.558 0 Td (ildren )Tj 0.0262 Tc 2.735 0 Td (treated )Tj 0.0212 Tc 3.201 0 Td (with )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0311 Tc 10.2 0 0 10.2 399.5104 72.7272 Tm (1000 )Tj EMC ET BT /T1_0 1 Tf 0.037 Tc 10.2 0 0 10.2 421.8382 72.7272 Tm (and )Tj ET BT /Suspect <>BDC 0.082 0.082 0.078 rg /T1_0 1 Tf 0 Tc 10.2 0 0 10.2 442.228 72.7272 Tm (1)Tj 0.216 0.216 0.212 rg 0.0124 Tc 0.358 0 Td (200 )Tj EMC /Suspect <>BDC 0.141 0.141 0.137 rg -0.0319 Tc 1.808 0 Td (!!g )Tj EMC /Suspect <>BDC 0.216 0.216 0.212 rg 0.0473 Tc 1.341 0 Td (GCS )Tj EMC ET BT 0.141 0.141 0.137 rg /T1_0 1 Tf 0.0489 Tc 10.2 0 0 10.2 502.1224 72.7272 Tm (per )Tj 0.216 0.216 0.212 rg 0.05 Tc 10.326 0 0 10.2 518.78 72.72 Tm (day )Tj ET endstream endobj 3 0 obj <>stream Hd͊zy8 >sRhF^#y QG#Oç==o/ϧ;c_mӷKv|~_oo~y>}~W=|z>{O݇q~?>Ï?o+~ߒ~;%zΏx߽w;>lp?(O?{wٸ^ PZUuTGu^5P5FjFDMԤU PjVjUmFmک]uPuNNE]E5|| _#_k55|| _#_k55|| _#_k55|| _#_k5Z||-_+_kZ||-_+_kZ||-_+_kZ||-_+_ku:||_'_uu:||_'_uu:||_'_uu:||_'_uz||=_/_z||=_/_z||=_/_z||=_/_ || ߀o77 || ߀o77 || ߀o77 || ߀o77 KG#(~? ?G#(~? ?G#(~? ?G#(~? ?z $߄o77MM&|| $߄o77MM&|| $߄o77MM&|| $߄o77MM&||3,ߌo77f||3,ߌo77f||3,ߌo77f||3,ߌo77f|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|ۯ\t;]~~߅ww;]~~߅ww;]~~߅ww;]~~߅w߁w;;|C߁w;;|C߁w;;|C߁w;;|C߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S ߅w]..|K ߅w]..|K ߅w]..|K ߅w]..|?|x>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 19883/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream 'ǔe+}kPϷNju Jk|b1Ѧe-\ct?HN&|d?v'g8#&X{Odd/}'%fnI o{u<#8Hؐ׫]c*y+ gcpܕdR8W-d9+j/խJcrL8VyCF}РGΜ͊O99uۮEV#=2U[s@~?Z\.FQ7#ؖ8/dԗy"{U] +Xo ]Ǣ q26 F_ -a~TI?፳ ـ-*/ 2 VN]zg7nk `Gnq&vͭm2~0#;R 7XX̚a9}F'/ `(WgOK~=RP[-Uy#{ϑbxw%@z(+?m 2Z閦q?5}JC %Iҙ=jpAMt_:8Bڣ-#B  {E*^'1l(OY-ndޗUlL؊Bjf0:ikB6B&5ju&U;*VӾ<&(LoIyn ͮG ,+aOY@Px,AĀ۶✔|5ԋq |D[{^AS > "\T ;zN{O/e7T=sCqۯUsMpDYiM8-`q~;rth:}c?ɦ~'Y";{;3 #[U&#]BhpU MA`81_"Oo@But+g쨤(I4#$0~j|R SHӥGֻ`YDd س@9ws|_q̼,sHlth1N9#Z22=)YA dsqce 6t9MH‘ܗPtz0"6Q\<%9ń5hT@Bhsl!xT nx(r`)qefs~.O@.Q4g}9`L#tnVwP%Qa8'l "oxgva.^BSk`#*rC7CgM%LFO KyJrS_Ȩw,2$\($])ڎO|n `?2M Pvdu9~A"ZL <7aJE i & \aL̆r2qRmp MO6zF2>)H*s'a~e/O.!*Cא>)vĻdC5Ms邵@,d`bI>JIsH;hҿ[&i4MTِ399ju mq=V; 6A쬟iVTT׌ᩳ7‹U)Gsco>]FSQ&Ī*&J&Ix^'?Bk\eDMet6]+C;^U+r/UF9i% ྡ| %)x혴 sX_UF?vMGLbD`"o_"&BDShfNeC)@Z+I地I򶊣 '*$fŕF]Rkc^'|FgTu<23A҅Ƹe{kbtʧK2X+rEO3yU3R5vY a ' GdP®>N3Kah0FKLI;JSxBR;| >?6xI7i^.ia8+|T /NɖGySE~ɘ<4$B4kK` Qp7l\͸{k #P(4R"3/!4Fx'`/.*ݰBNI'oLPF  o&*/qU!FI{V:8h&{2MV3lr`NZ# I9| 3k&"& {?_PȡzfM?2;KAX^V!J#fU t `N?J۪VF̃ R]Xp[+'.ZX0Փr)-C2dմE889 gAҐ{K@(XdG=SuKOG8pNspE43'ɻzn\C{!H(? n ؐrC )sW 87We5;#t :ǣv Zeܼ'XY4S`fS''DJQ{IEb[64{>0/Ϛ Q%`fc xzK<?zԃv> e􍁙'z'_-`p6b)X15TװF.cmrJMa0<œY33U0@e_GQ&uOMWݠe/&G=$jaxǁD=d.멺4]{rj8y Zy;[i=wAY|DrqM>Sz{^$[omh,.M %oc7˅pQK}x8> P zϕ2-O~S 0 /bUc_2L5]'se֡AkӉA9>/*{%dTfeV4Jl$Mf~CqҎn@V0+RY?6kz䛆0R{]k1g]@6XczQ^Х{oØ+`R~3ʹS/֪ zh&|;7pֲ#>e~{eaˀHĦ`wusr–` Qh@ > n2 9'2tLE4i;8dZqD>wlLm2+DGާQCQ9ȳ'pGb%=G)GP]ZM)ͻEk$`G9Æ Olʄx_ HG/<.t__ڱf$1'EVp dP B1)4iy"R(`wllq,"3CFקbe6zoq,m`jԘz*gbwg1OĢF1 L LJd9[_%#Mܼ׌)1:ύ%@İ1}bmB;ih`9 ek0}l?"}FoFfuQD̉Shw'*mf滎'o\Yd47hO\aA )Q/qE `~ݘw6۩gKjC;=R(6(Q{Z"Gڝ$i B5 ŷzIO m])= # l=%U ^^aef `ރlM+ wac9QK ]kZ;5ߗMլo3鞳lݜauLD W6{Y6YC#j/%b 34aҦMg]XG]X~]tgP;ܘF ۯ&wj&mN1F=" < wK2G 3>V<|]az=یh'U@Z ao$#:74M (ullqG7\j]%_1bxvw>D}NR[JVCJ tm γp #B:NzCM> ד0)tN4B yYdq6(U3R!oT~M΂zЊw*ie+v%1;VŔ㸪iEMZ܏zj3х nJ;Ʌ w'{h!]g/U"隆"N]=[pFm2/Ib:6V; *o4XAWue=V 2OxnQ!>?:j,P@ø'8K@!ZtټsKqynѵ'6fHR F(.{Oyylt2|HDOsiG9F~wKjSOs,]9$<}qA]*X U43_sg7BE ak;;*M}@`e1޾CK*c0|JwvPmxXt"F;V433Hle3*޷հy7|™|֨oߨE|9`Z !2BsFD*^x޶".kgdU>)vÊ+ 9TvAHMWPmA&TG d7eL o^uG Sf}G!d״FGXiŽd2 օ?FO4wOq2ENœU~㜢2aX ΋tƈ\PLᗢ ri=1_HtƹZ%ߖс"8z^jF $ ы&o0#TOHKK5&LZxmLg[X$Gb6tW1} l.Ǡ]D%[ I=i mVNgE=gOw"to]՗_0]jZ!5P" \`~ /^:iG?уT (#1f 7_Uiũ|;s4Qq;lf0s|v*eDj87nz,~[ )}T=ZrdQĊKӐZ+\ Osh\ R9;c$TcۯAmtTV M= ,w*qku 8z;j S Biɮ6$+>z~?:sO)N7:C 'f6ʡNYFx " R XBc>jـ^&I>8Z@)Z<ì:me9]$YcZEBW4)gTԗkr#B M"|` Y43Hj.{H(JR 0ULebkqY0ZwUG!sÚ1}\q O*H5z,DT7w2.AS1*<nRwHh5dr(9ջq tX#2.Qْ|a1BGP"IMg' D4(ݜJA̵;A7N%=6&oFNԳk!xП>.X:LO_EZƃ,h8A e9*[\nlSP#AR+y]n-.~:c7JW wgC߀ǜ"@V{ ٯ>k!SVގܡS uh,7Áy@Ǟ#vSXt1Sp׷| d|FՓ۠Vr3PUvf!y3ǩDG#p[j6v^%bR|y_PZ9m`a0@ %5v/L,0cDƖ=~{,@64[JbZm4wX3S0"D/%co,1&2H@ ?hR3[VW yYߧkyUIj/z_##Ds{epG6Y%sdJ9 5eE%Ta5pUO){UU`(^yaXp{T.3ruKBsmpG'rRHrp.><\8G5 JhnXbIrE88tҤV˔;[9xIH"}dOާFT#).Ț~$썏=Jb7ռ6S05?bۑ%Vz]Mb>3徼C\t<(4˃z>,? c_WFzJT] /Pȹkeȼ[Qm$]Cy"޸#J92[nb8kydE@jcÏDr8)(vտd;lHqOièO4J!Xw +|{/G[2s!&92׍ ۊ)'˗~H )zMMIED/&OҮ6ށsvs-23^G @%ߜkǚ"ŕ3$D 6L׈b'F1Q4i(7uX+tSXIAvk5a,:PdPнxlVkb܅299tݣn ,jמ 'ryƏh<:C WK 踸~ͺ~jIPar=:^C3;$)ą4=5q0y$W@ 8cyk&F+g## եLvh(&&㒸4b/'V -{֦feU޸e2ī.F)t"\,[ʆVr;td%ad"v;^1a3RL YZoqbα}QC庖hߦ,D(öWɮ Y*I*W6ڌ4 Aj1+te6e& wwHg"=0TL8+ n$ qaPɡ+蕟0$JPdJ/kK'OK=yZ'pe5i9td-i^O r\ ^.ƈ]'Xē2-|e4o]4Eg!"6¼#`j#吏սŔVU>wdN`R { f~@ *^vIK QJsB0.: 'ҵJLϐ|fѫԃ9mèYW֦rXśʪ(0m$Qt%2 e,grp]gX7woMo$,fNB`Yz-j^u0T/0(Dqލ*oA~ yob:̯,@6g]!4"0&䑄£K;G㶣>=)pۙ=;F~B$IPUn), ƾ:E>9썷G,OF:t9ӏ79\Y J xv#tW?t}p"~Xڌ6/4 HmluB>R] 1T 9š jXEqTC۳VE8}9qk:lL#_͈ FuZlVAtg@fRGU3Q>A#Y a]bx' ^/@rlS@ΧA3.1ûtr7%33=DZn)\t"Q*Kv }y@cdB-+%F+qe1>5Klms_naC@9LWz\]c[y_vV]oYYXphj^|2q#$W`"^'H\@ $[q9'>] B)O19UQ0'_P׹;1Kzˎ2i -mZArgC[~!̾7)K37V \ PhسA+={(A\ejwNb;W$'\dHl#sӍE)D[ыu'-4=U7]Vw)c&Yج}$TRqfQ{f%hBj.g07>P,m>mL2 /P\=9;CXsu^2èjȮrwG;),u{@^Z6;.\#Tٝy(Yw> X2;au[;*3ۡd3k;-yw,G,mofE)Rggӳ^ʫ}N["C;'-PMf1ݩNc 8ZZ'դ[ Ho[f+y1nڈ4Yҹ:\@j7oDBlN0=. *+jm8$nTyHwCS9%iE yBK94IY;*>1XߦVťKD.Jڜ)fca.K,:51 ,EO 4IY]rt}sH/TG>.tڨo'W"oRī+d#IwݬQo>FlfՓJ@  !c&;] fh9]ղ\"nwb(sG0~ ֚:5Ֆ;;;{))1% Ӊ֥k̉r{XhUð״@F t*qTWJϗb $St0/ 77({m]" QVVxuA܋rQ{O:yfDj(ȈNo@ ` 0HP6A +}Me>H<.:_!x~D_6Tm7BUacFGJ6zq7Kp9UFJAB l.6lo11Ums̚ s :(N NUѴ |ۭn_W;=X޸鏉^ib饤j nםLN)5,]LXڎ%c d]%~)RQ ^AS X1l-t=x`AE_  43VE)<tDgj:$ν*v !2FƲ(RN}ͩCIUjc}!.`0=T(?ٙ];*/i 0SC?0Mfffر#wf69gư5 ITgA`!S1&Y[mzVr~8Q4W3⣈b}i֞).6[`6$@_%4 [3z#[{4[ZװEO#>Ӱ8d; 85C*d:􌏇cGf# zLNۙ>c|,00fAG %vYVlj(E ,@iJr ,Nkb%t|Ppd?A2/BMC[tqOF |\o`)^K?LX /J_81ku FHypҞolB: ٫2$9jI ^ggJ:9έӈNHUݑūحMϛc<^tRŅdyK .݌{N[᷌LMx? LTk?S24EB]9rBa_ *\A 1Ep_$-Vz 9l~EzyW:f_^U~kΗեl+UrvNӛqn:OHJ $b('M 5 |nE $U8n;3%CW,}[a ck:= : Jț?iZv߹f\B^Z֮E b4(3 1Ui} DR*)1ʩOo!?E~T}x^KhQ)-{_G67fe7ɑN/TL6vGVS.4Wq.W?B2*r@|K-*p臨gN/hno)ABȣ2n\D+ B/$v)̹Dp:vhF$-hfo7uBS:5,+8>M}clwte>P"t,[B2\(9x&' R1 ׁ MA:{ʠwO/ 3U9@p8<=r{OBh'Hx$\>3M = %(P4#ENT! $Q2q獮rAΈ@gUy^#{U[el)CY^9E0YxPl~CmXZ.LJ{Eu+VULx5p,UЅ5Q>ҙ,G)Ew>B~Wza1CѫH9߮|CTXnt} פ54rDɞ15niҁ~T|ImI] "}[.eL 9"0驑fi-+qZ=Fɍ*Qϵ,cX1$$A[T s<MkkalZx'[KG^CcBW3X|Oix>#8D42ivǀ\}i+c~[mmOX ߟe^&x8b]RPPqh @4`_4]F lֈȫ܁QEf"/b# c(W5h8z|5=VkQX@gm/owtMBہZ_*8q$]Z=Gx5c(RK=!0*,tWwT`&)։=2>O EVwsAaDb}*kX `C``a?*0 &zt })YdSR.A676F V ̤?;a9G%j歽2PS8mvVS-5ʎ,(BQŝ哱 5vN ={`?5ڱҳD0tDd+|mɵ]unl)y!"r8x*Ci]Қ0N,Ð9_pӾǥZ&oBV]w=QKAڒ': >F;GؤBPy8ŜQARJQcԒas6ħI ̭lQEp:xhX5]*4\{ X갵tfnޚ]Lie>H? k=%jNpSF 3[|w'ț`Br ƴ 73c:*7.em xEs5>^P]e0JnyƇEADo\6'?tU?̮7nsYhZ @}fYDPL[j{"` +Ivh#ElZ$ej suH1z\a52ѵʷ*ڈ)O?\37?؍27ƅ0٘0!@u8/f[]Z#}1;'E b.WF|O ȏH'KYEF5lŔx%i2}~[{,;3R:u\tH>ũ(A@G05*Q'p$}J;֡;)+C' ٤fM{L=TY׳:>EN<([iGE!JK]*;MS} m$)_eRA A>ܴS4^n2?g,bcMaSLy^و Qvrji#pSΗ?yk(["5[H6!U&Ζ`Z/,WNoR#/ϖ7_ GG؆ #In޶LADo/AӚ wHvufCF]N66֨L|^FN#®.IF4ѱӂok2p+<$mMDNqz]I xCXMk,BU0H>jy4%4ؙ`":tOQ?~}doD[Ef~rәhUbOf 1̪V׀DZÅƋv:\m`YE_}mAȻy4 Py7vT7+#Ԡ=[ߖPkOZpQM~ʂZԃ*C>7Ӹ]ϻ[f :e}\j m=mNs]2A:4Ɗ7^ "ynRpU}_4/zϏ7P wz{b”5`$=q{YHd 9}Gqvh`ܣ'M8[y:0O-t4$xCp@3'kgi bY5To^vhLXe*&l:!kIL7dZ1Y ;UUŏAoF?BE-`A gsk[";@n\=x8NuM""xK `O lAw-58e1Yk7)=;ScǟA$,L9*-4%Q,5Y|J9p{Iyy]t`vq_i}t0fŞ͜?n]`.XN60x܅(Tiٻq#}'y(ZDrvSXq%K-wt+%i7:HBJy.쇲aYFH``ml5P܇;qxE^@S_1$vɯ+jD%idip>ϢVB@ Q^%N bS nnl~^)0X=V7:hǸ1FZl9c͒Z=t&=Oedo愕5ȪZHv_X+{LҠ 2q 7OntF&Vyi_2r#Gf1LJNU'CA'.{ڕz}k ,xġg{B+xm;ԍT57>8uUD(@l >ܱF0{.`v9 !=<j8rzN_b}uTAq WyWYI rv\6KTY6p?feHi<rU),ۊ- 54bL>W@d#eh'R*\Tl֯qVeQUo"st{(Ab5_vbp?Mzz*efQ%7g7FK=|=lmnI'{Ѹc+t^둅|ɋJ0H.`[dZߔئ~/S 3@٫HMktfq{}KŦ) endstream endobj 5 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdrcolrujp2cOQ/R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ! :  ):PF o   endstream endobj 6 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr colryjp2cOQ/  R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴt @:  ( |!@|!>o` Ҁ   endstream endobj 7 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr,colrmjp2cOQ/,,R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ t ! :  :&|"    endstream endobj 8 0 obj <>stream jP ftypjp2 jp2 jpxbjpx rreq@ --jp2hihdr6colrrjp2cOQ/66R \#B@HHPHHPHHPHHP880 ]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHP880]$B@HHPHHPHHPHHPHHPϴ [t ! ": h@ |"i|"^    endstream endobj 9 0 obj <>stream h 0+h !N< endstream endobj 10 0 obj <>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Type/Page>> endobj 11 0 obj <>stream q 0.192 0.192 0.192 rg 595.1999969 0 0 840.9600067 0 0 cm /Im0 Do Q BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.05 Tc 3 Tr 8.8675 0 0 8.1 167.03 755.76 Tm (URINE )Tj EMC /Suspect <>BDC 8.7667 0 0 8.1 200.07 755.76 Tm (CORT)Tj 0.122 g 0 Tc 8.1 0 0 8.1 226.02 755.76 Tm (I)Tj 0.251 0.251 0.247 rg 0.05 Tc 8.3545 0 0 8.1 229.29 755.76 Tm (SOL )Tj EMC ET BT /T1_0 1 Tf 8.4949 0 0 8.1 250.55 755.76 Tm (AND )Tj 8.7462 0 0 8.1 274.02 755.76 Tm (INHA)Tj 0.122 g 0 Tc 8.1 0 0 8.1 299 755.76 Tm (L)Tj 0.251 0.251 0.247 rg 0.0438 Tc 0.711 0 Td (ED )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 8.782 0 0 8.1 320.07 755.76 Tm (CORTICOSTEROIDS )Tj EMC ET BT 0.184 g /T1_0 1 Tf 0.0168 Tc 9.8 0 0 9.8 511.64 755.29 Tm (435 )Tj 0.251 0.251 0.247 rg 0.0479 Tc -47.263 -2.401 Td (than )Tj 0.0228 Tc 2.149 0 Td (in )Tj 0.0321 Tc 1.076 0 Td (children )Tj 0.0375 Tc 3.829 0 Td (treated )Tj 0.0299 Tc 3.283 0 Td (with )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0267 Tc 9.8 0 0 9.8 170.2472 731.7602 Tm (800 )Tj EMC /Suspect <>BDC -0.035 Tc 6.162 0 0 9.8 188.13 731.76 Tm (J.Lg )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 10.183 0 0 9.8 200.66 731.76 Tm (per )Tj 0.0264 Tc 9.8 0 0 9.8 216.87 731.76 Tm (day. )Tj 0.184 g 0.05 Tc 9.9723 0 0 9.8 237.03 731.76 Tm (The )Tj 0.251 0.251 0.247 rg 0.0168 Tc 9.8 0 0 9.8 256.72 731.76 Tm (long )Tj 0.0275 Tc -21.251 -1.077 Td (term )Tj 0.0171 Tc 2.686 0 Td (clinical )Tj 0.0134 Tc 3.816 0 Td (significance )Tj 0.05 Tc 11.1292 0 0 9.8 168.37 721.21 Tm (of )Tj 0.0259 Tc 9.8 0 0 9.8 184.78 721.21 Tm (this )Tj 0.0462 Tc 2.303 0 Td (has )Tj 0.05 Tc 9.8429 0 0 9.8 228.95 721.21 Tm (yet )Tj 9.8951 0 0 9.8 249.1 721.21 Tm (to )Tj -0.0028 Tc 9.8 0 0 9.8 265.45 721.21 Tm (be )Tj 0.0271 Tc -22.199 -1.127 Td (elucidated. )Tj 0.184 g -0.035 Tc 9.7895 0 0 9.8 141.07 680.89 Tm (References )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0243 Tc 8.1 0 0 8.1 48.42 664.56 Tm (I. )Tj EMC ET BT /T1_0 1 Tf 0.0122 Tc 8.1 0 0 8.1 61.8822 664.56 Tm (Bisgaard )Tj 0.0466 Tc 4.326 0 Td (H, )Tj -0.0048 Tc 1.728 0 Td (Nielsen )Tj 0.05 Tc 8.1213 0 0 8.1 141.56 664.56 Tm (MD, )Tj 0.0293 Tc 8.1 0 0 8.1 162.71 664.56 Tm (Andersen )Tj -0.0203 Tc 4.678 0 Td (P. )Tj /T1_1 1 Tf 0.05 Tc 8.2481 0 0 8.1 212.09 664.56 Tm (et )Tj 8.2134 0 0 8.1 223.63 664.56 Tm (al)Tj 0.435 0.435 0.431 rg 0 Tc 8.1 0 0 8.1 230.32 664.56 Tm (. )Tj /T1_0 1 Tf 0.828 0 Td (-)Tj 0.251 0.251 0.247 rg 0.0177 Tc 1.254 0 Td (Adrenal )Tj 0.021 Tc -24.662 -1.126 Td (function )Tj 0.0095 Tc 3.736 0 Td (in )Tj 0.0268 Tc 1.065 0 Td (asthmatic )Tj 0.0263 Tc 4.207 0 Td (children )Tj 0.0218 Tc 3.741 0 Td [(treated )63(with )]TJ 0.0216 Tc 5.156 0 Td (topical )Tj 0.0187 Tc 3.075 0 Td (glucocorticoster\255)Tj 0.329 0.329 0.326 rg 0.0002 Tc -20.979 -1.067 Td (oids. )Tj 0.251 0.251 0.247 rg /T1_1 1 Tf -0.035 Tc 7.8768 0 0 8.7 66.15 646.8 Tm (ln: )Tj /T1_0 1 Tf 0.0243 Tc 8.1 0 0 8.1 76.72 646.8 Tm (Glucocorticosteroids )Tj 0.0095 Tc 9.009 0 Td (in )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0262 Tc 8.1 0 0 8.1 157.8415 646.8 Tm (cllildhood )Tj EMC ET BT /T1_0 1 Tf 0.0319 Tc 8.1 0 0 8.1 194.3239 646.8 Tm (asthma. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0011 Tc 8.1 0 0 8.1 223.0546 646.8 Tm (S. )Tj EMC ET BT /T1_0 1 Tf 0.0301 Tc 8.1 0 0 8.1 231.7621 646.8 Tm (Godfrey )Tj 0.0194 Tc 3.732 0 Td (ed., )Tj /T1_1 1 Tf -0.0005 Tc -26.411 -1.126 Td (Excerpta )Tj -0.0043 Tc 4.032 0 Td (Medica, )Tj /T1_0 1 Tf 0.0278 Tc 3.663 0 Td (Amsterdam, )Tj 0.184 g -0.0305 Tc 5.596 0 Td (1986)Tj 0.329 0.329 0.326 rg 0 Tc 1.856 0 Td (, )Tj 0.251 0.251 0.247 rg -0.0168 Tc 0.591 0 Td (87)Tj 0.529 g 0 Tc 1.014 0 Td (-)Tj 0.251 0.251 0.247 rg 0.0097 Tc 0.533 0 Td (92. )Tj -0.035 Tc 7.5852 0 0 8.1 47.48 629.05 Tm (2. )Tj 0.0371 Tc 8.1 0 0 8.1 61.4 629.05 Tm (Law )Tj 0.05 Tc 8.1555 0 0 8.1 81.52 629.05 Tm (CM, )Tj 0.0388 Tc 8.1 0 0 8.1 102.2 629.05 Tm (Marchant )Tj 0.05 Tc 8.2336 0 0 8.1 140.11 629.05 Tm (JL, )Tj 8.3064 0 0 8.1 155.96 629.05 Tm (Honour )Tj 0.0131 Tc 8.1 0 0 8.1 188.12 629.05 Tm (JW. )Tj /T1_1 1 Tf 0.0046 Tc 2.248 0 Td (et )Tj -0.035 Tc 8.0998 0 0 8.1 216.91 629.05 Tm (al. )Tj /T1_0 1 Tf 0 Tc 8.1 0 0 8.1 230.31 629.05 Tm (-)Tj 0.034 Tc 1.142 0 Td (Nocturnal )Tj 0.0157 Tc -23.718 -1.127 Td (adrenal )Tj 0.0165 Tc 3.433 0 Td (suppression )Tj -0.035 Tc 7.9356 0 0 8.1 118.02 619.92 Tm (in )Tj 0.0342 Tc 8.1 0 0 8.1 126.64 619.92 Tm (asthmatic )Tj 0.0178 Tc 4.385 0 Td (children )Tj 0.0344 Tc 3.741 0 Td (taking )Tj 0.0164 Tc 2.957 0 Td (inhaled )Tj 0.0123 Tc 3.388 0 Td (beclome\255)Tj 0.0251 Tc -24.241 -1.065 Td (thasone )Tj 0.0282 Tc 3.548 0 Td (dipropionate. )Tj /T1_1 1 Tf 0.0089 Tc 6.064 0 Td (Lancet, )Tj /T1_0 1 Tf -0.0261 Tc 3.452 0 Td (1986, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 8.5396 0 0 8.1 174.18 611.29 Tm (I, )Tj EMC ET BT /T1_0 1 Tf 0.025 Tc 8.1 0 0 8.1 182.31 611.29 Tm (942-944. )Tj -0.035 Tc 7.7865 0 0 8.1 47.43 602.17 Tm (3. )Tj 0.0363 Tc 8.1 0 0 8.1 61.4 602.17 Tm (Bjorkander )Tj 0.184 g 0 Tc 8.6 0 0 8.6 105.07 602.17 Tm (J)Tj 0.329 0.329 0.326 rg 0.437 0 Td (, )Tj 0.251 0.251 0.247 rg 0.0319 Tc 8.1 0 0 8.1 116.61 602.17 Tm (Formgren )Tj 0.0466 Tc 4.858 0 Td (H, )Tj 0.0354 Tc 1.719 0 Td (Johansson )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0011 Tc 8.1 0 0 8.1 210.57 602.17 Tm (S, )Tj EMC ET BT /T1_0 1 Tf 0.0173 Tc 8.1 0 0 8.1 223.1574 602.17 Tm (Milquist )Tj -0.0175 Tc 4.207 0 Td (E. )Tj 0.529 g 0 Tc 1.535 0 Td (-)Tj 0.251 0.251 0.247 rg 0.0202 Tc -27.431 -1.126 Td (Methodological )Tj 0.0249 Tc 7.165 0 Td (aspects )Tj 0.05 Tc 8.3916 0 0 8.1 134.8 593.05 Tm (on )Tj 0.0066 Tc 8.1 0 0 8.1 147.76 593.05 Tm (clinical )Tj 0.0161 Tc 3.622 0 Td (trials )Tj 0.0218 Tc 2.668 0 Td (with )Tj 0.0164 Tc 2.422 0 Td (inhaled )Tj 0.0163 Tc 3.673 0 Td (cortico\255)Tj 0.0097 Tc -24.833 -1.067 Td (steroids: )Tj 0.0197 Tc 3.746 0 Td (results )Tj 0.05 Tc 8.9033 0 0 8.1 101.2 584.41 Tm (of )Tj 0.022 Tc 8.1 0 0 8.1 109.9 584.41 Tm (two )Tj 0.0243 Tc 1.77 0 Td (comparisons )Tj 0.0099 Tc 5.581 0 Td (between )Tj 0.022 Tc 3.67 0 Td (two )Tj 0.0251 Tc 1.707 0 Td (steroid )Tj 0.0249 Tc 3.085 0 Td (aerosols )Tj 0.0095 Tc 3.675 0 Td (in )Tj 0.0232 Tc -27.249 -1.126 Td (patients )Tj 0.0021 Tc 3.79 0 Td (with )Tj 0.0319 Tc 2.302 0 Td (asthma. )Tj /T1_1 1 Tf -0.0152 Tc 3.869 0 Td (Eur )Tj /T1_2 1 Tf 0 Tc 7.7 0 0 7.7 143.45 575.29 Tm (J )Tj /T1_1 1 Tf 0.0005 Tc 8.1 0 0 8.1 151.74 575.29 Tm (Respir )Tj -0.0143 Tc 3.143 0 Td (Dis)Tj 0.435 0.435 0.431 rg 0 Tc 1.416 0 Td (, )Tj 0.251 0.251 0.247 rg /T1_0 1 Tf -0.0261 Tc 0.791 0 Td (1982, )Tj -0.0201 Tc 2.63 0 Td (63, )Tj 0.0092 Tc 1.72 0 Td (\(suppl. )Tj -0.0288 Tc 3.473 0 Td (122\), )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0194 Tc 8.1 0 0 8.1 47.7198 566.6473 Tm (108-118)Tj 0.031 g 0 Tc 3.451 0 Td (. )Tj EMC ET BT 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0357 Tc 8.1 0 0 8.1 46.5291 557.5267 Tm (4. )Tj 0.329 0.329 0.326 rg 0.0093 Tc 1.772 0 Td (Clissold )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0178 Tc 8.1 0 0 8.1 90.0909 557.5267 Tm (SP, )Tj EMC ET BT /T1_0 1 Tf 0.0075 Tc 8.1 0 0 8.1 103.1643 557.5267 Tm (Heel )Tj 0.184 g 0.0333 Tc 2.252 0 Td (RC)Tj 0.329 0.329 0.326 rg 0 Tc 1.406 0 Td (. )Tj 0.529 g 0.484 0 Td (-)Tj 0.184 g 0.0181 Tc 0.836 0 Td (Budesonide)Tj 0.329 0.329 0.326 rg 0 Tc 4.839 0 Td (: )Tj 0.251 0.251 0.247 rg 0.489 0 Td (a )Tj 0.0268 Tc 0.663 0 Td (preliminary )Tj 0.0016 Tc 5.153 0 Td (review )Tj 0.329 0.329 0.326 rg 0.05 Tc 8.9033 0 0 8.1 257.68 557.53 Tm (of )Tj 0.251 0.251 0.247 rg 0.0106 Tc 8.1 0 0 8.1 266.33 557.53 Tm (its )Tj 0.0323 Tc -27.072 -1.126 Td (pharmacodynamic )Tj 0.0246 Tc 8.296 0 Td (properties )Tj 0.05 Tc 8.4599 0 0 8.1 151.59 548.41 Tm (and )Tj 0.0307 Tc 8.1 0 0 8.1 168.46 548.41 Tm (therapeutic )Tj -0.0078 Tc 5.147 0 Td (efficacy )Tj 0.0095 Tc 3.617 0 Td (in )Tj 0.0409 Tc 1.243 0 Td (asthma )Tj 0.0248 Tc -25.007 -1.068 Td (and )Tj 0.0076 Tc 1.905 0 Td (rhinitis. )Tj /T1_1 1 Tf -0.0055 Tc 3.567 0 Td (Drugs, )Tj /T1_0 1 Tf -0.0113 Tc 3.156 0 Td (1984, )Tj -0.023 Tc 2.517 0 Td (28, )Tj 0.0321 Tc 1.543 0 Td (485-518. )Tj /T1_1 1 Tf -0.035 Tc 7.5657 0 0 8.1 46.96 530.65 Tm (5. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0163 Tc 8.1 0 0 8.1 60.81 530.65 Tm (Stiksa )Tj EMC /Suspect <>BDC 0.05 Tc 10.4831 0 0 8.1 84.85 530.65 Tm (0, )Tj EMC ET BT /T1_0 1 Tf 0.0338 Tc 8.1 0 0 8.1 96.88 530.65 Tm (Glennow )Tj 0.329 0.329 0.326 rg 0.05 Tc 8.1322 0 0 8.1 131.44 530.65 Tm (C, )Tj 0.251 0.251 0.247 rg 0.0349 Tc 8.1 0 0 8.1 142.52 530.65 Tm (Johanesson )Tj -0.0239 Tc 5.343 0 Td (N. )Tj 0.329 0.329 0.326 rg 0 Tc 1.465 0 Td (-)Tj 0.251 0.251 0.247 rg 0.05 Tc 8.34 0 0 8.1 205.43 530.65 Tm (An )Tj 0.0307 Tc 8.1 0 0 8.1 219.28 530.65 Tm (open )Tj 0.0203 Tc 2.43 0 Td (cross-over )Tj -0.0012 Tc -23.696 -1.068 Td (trial )Tj 0.0218 Tc 1.957 0 Td (with )Tj 0.0286 Tc 2.077 0 Td (budesonide )Tj 0.0248 Tc 5.085 0 Td (and )Tj 0.0208 Tc 1.848 0 Td (beclomethasone )Tj 0.0374 Tc 6.922 0 Td (dipropionate )Tj 0.0095 Tc 5.749 0 Td (in )Tj 0.0316 Tc 1.077 0 Td (patients )Tj 0.0218 Tc -24.773 -1.125 Td (with )Tj 0.0259 Tc 2.314 0 Td (bronchial )Tj 0.0319 Tc 4.374 0 Td (asthma. )Tj /T1_1 1 Tf 0.0144 Tc 3.751 0 Td (Eur )Tj /T1_2 1 Tf 0 Tc 7.7 0 0 7.7 146.33 512.89 Tm (J )Tj /T1_1 1 Tf 0.0005 Tc 8.1 0 0 8.1 154.62 512.89 Tm (Respir )Tj ET BT /Suspect <>BDC /T1_1 1 Tf 0.0059 Tc 8.1 0 0 8.1 178.6365 512.89 Tm (Dis, )Tj EMC ET BT /T1_0 1 Tf -0.0261 Tc 8.1 0 0 8.1 196.5132 512.89 Tm (1982, )Tj 0.0095 Tc 2.511 0 Td (63, )Tj 0.0191 Tc 1.66 0 Td (\(suppl. )Tj -0.0288 Tc 3.414 0 Td (122\), )Tj 0.0242 Tc -26.105 -1.067 Td (266-267. )Tj -0.0143 Tc -0.006 -1.127 Td (6. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0423 Tc 8.1 0 0 8.1 60.4413 495.1186 Tm (Warner )Tj EMC /Suspect <>BDC 0.184 g 0.05 Tc 8.3272 0 0 8.1 92.59 495.12 Tm (JO)Tj 0.329 0.329 0.326 rg 0 Tc 8.1 0 0 8.1 102.59 495.12 Tm (, )Tj EMC ET BT 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0117 Tc 8.1 0 0 8.1 110.8439 495.12 Tm (Reiser )Tj -0.035 Tc 8.0557 0 0 8.1 138.2 495.12 Tm (J. )Tj 0.529 g 0 Tc 8.1 0 0 8.1 149.67 495.12 Tm (-)Tj 0.251 0.251 0.247 rg 0.0266 Tc 1.367 0 Td (Inhaled )Tj 0.0173 Tc 3.969 0 Td (glucocorticosteroids )Tj 0.05 Tc 8.2876 0 0 8.1 267.29 495.12 Tm (in )Tj 0.0214 Tc 8.1 0 0 8.1 46.48 486 Tm (childhood )Tj 0.0319 Tc 4.563 0 Td (asthma. )Tj /T1_1 1 Tf -0.035 Tc 7.6628 0 0 8.4 113.84 486 Tm (In: )Tj /T1_0 1 Tf 0.0243 Tc 8.1 0 0 8.1 126.16 486 Tm (Glucocorticosteroids )Tj 0.0095 Tc 9.127 0 Td (in )Tj 0.0288 Tc 1.184 0 Td (childhood )Tj 0.0319 Tc 4.622 0 Td (asthma. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.8213 0 0 8.1 46.42 477.37 Tm (S. )Tj EMC ET BT /T1_0 1 Tf 0.0301 Tc 8.1 0 0 8.1 55.6 477.37 Tm (Godfrey )Tj 0.0194 Tc 3.851 0 Td (ed., )Tj /T1_1 1 Tf 0.0249 Tc 1.856 0 Td (Excerpta )Tj 0.0056 Tc 4.091 0 Td (Medica, )Tj /T1_0 1 Tf 0.0344 Tc 3.663 0 Td (Amsterdam, )Tj -0.0261 Tc 5.656 0 Td (1986, )Tj -0.0272 Tc 2.453 0 Td (78)Tj 0.435 0.435 0.431 rg 0 Tc 1.007 0 Td (-)Tj 0.251 0.251 0.247 rg -0.035 Tc 7.9658 0 0 8.1 243.22 477.37 Tm (84. )Tj 7.6478 0 0 8.1 46.48 468.25 Tm (7. )Tj -0.0087 Tc 8.1 0 0 8.1 60.45 468.25 Tm (Willey )Tj 0.184 g 0.05 Tc 8.695 0 0 8.1 86.36 468.25 Tm (RF)Tj 0.329 0.329 0.326 rg 0 Tc 8.1 0 0 8.1 97.31 468.25 Tm (, )Tj 0.251 0.251 0.247 rg 0.05 Tc 8.1884 0 0 8.1 102.64 468.25 Tm (Godden )Tj 0.0389 Tc 8.1 0 0 8.1 134.36 468.25 Tm (DJ, )Tj 0.031 Tc 1.891 0 Td (Carmichal )Tj 0.05 Tc 8.46 0 0 8.1 188.59 468.25 Tm (J, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0263 Tc 8.1 0 0 8.1 198.2 468.25 Tm (Preston )Tj EMC ET BT /T1_0 1 Tf 0.039 Tc 8.1 0 0 8.1 227.4815 468.25 Tm (P, )Tj 0.0478 Tc 1.305 0 Td (Frame )Tj 0.184 g 0.05 Tc 8.1464 0 0 8.1 263.96 468.25 Tm (M, )Tj 0.251 0.251 0.247 rg 0.0421 Tc 8.1 0 0 8.1 46.48 459.61 Tm (Crompton )Tj 0.05 Tc 8.3645 0 0 8.1 84.88 459.61 Tm (GK. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 8.1 0 0 8.1 103.11 459.61 Tm (-)Tj EMC ET BT /T1_0 1 Tf 0.0325 Tc 8.1 0 0 8.1 110.7969 459.61 Tm (Comparison )Tj 0.05 Tc 9.4598 0 0 8.1 155.91 459.61 Tm (of )Tj -0.0066 Tc 8.1 0 0 8.1 166.54 459.61 Tm (twice )Tj 0.0215 Tc 2.481 0 Td (daily )Tj 0.0311 Tc 2.489 0 Td (administration )Tj 0.05 Tc 9.4598 0 0 8.1 259.59 459.61 Tm (of )Tj 0 Tc 8.1 0 0 8.1 270.16 459.61 Tm (a )Tj -0.0308 Tc -27.606 -1.126 Td (new )Tj 0.0258 Tc 2.006 0 Td (corticosteroid )Tj 0.022 Tc 6.174 0 Td (budesonide )Tj 0.0021 Tc 5.153 0 Td (with )Tj 0.0208 Tc 2.195 0 Td (beclomethasone )Tj 0.032 Tc 7.1 0 Td (dipropionate )Tj 0.0309 Tc 8.532 34.784 Td (four )Tj -0.0068 Tc 2.201 0 Td (times )Tj 0.0215 Tc 2.541 0 Td (daily )Tj 0.0095 Tc 2.49 0 Td (in )Tj 0.0253 Tc 1.191 0 Td (treatment )Tj 0.05 Tc 8.9033 0 0 8.1 403.12 732.24 Tm (of )Tj 0.0373 Tc 8.1 0 0 8.1 412.72 732.24 Tm (chronic )Tj 0.05 Tc 8.1358 0 0 8.1 441.52 732.24 Tm (asthma)Tj 0.122 g 0 Tc 8.1 0 0 8.1 466.87 732.24 Tm (. )Tj 0.184 g /T1_1 1 Tf 0.0078 Tc 0.74 0 Td (Br )Tj 0.251 0.251 0.247 rg /T1_2 1 Tf 0 Tc 7.7 0 0 7.7 483.77 732.24 Tm (J )Tj /T1_1 1 Tf -0.0143 Tc 8.1 0 0 8.1 491.6 732.24 Tm (Dis )Tj 0.329 0.329 0.326 rg 0.0183 Tc 1.748 0 Td (Chest, )Tj 0.251 0.251 0.247 rg /T1_0 1 Tf -0.0261 Tc -25.437 -1.065 Td (1982, )Tj -0.0201 Tc 2.453 0 Td (76, )Tj 0.0335 Tc 1.599 0 Td (61-68. )Tj -0.0038 Tc -4.153 -1.127 Td (8. )Tj 0.0352 Tc 1.735 0 Td (Adelroth )Tj 0.0417 Tc 4.204 0 Td (E, )Tj 0.026 Tc 1.304 0 Td (Rosenthall )Tj -0.0181 Tc 4.978 0 Td (L, )Tj 0.0239 Tc 1.299 0 Td (Glennow )Tj 0.05 Tc 8.1322 0 0 8.1 442.48 714.48 Tm (C. )Tj 0.529 g 0 Tc 8.1 0 0 8.1 453.99 714.48 Tm (-)Tj 0.251 0.251 0.247 rg 0.0485 Tc 1.014 0 Td (High )Tj 0.184 g 0.0442 Tc 2.543 0 Td (dose )Tj 0.251 0.251 0.247 rg 0.0361 Tc 2.312 0 Td (inhaled )Tj 0.022 Tc -24.998 -1.126 Td (budesonide )Tj 0.0095 Tc 5.146 0 Td (in )Tj 0.043 Tc 1.191 0 Td (the )Tj 0.184 g 0.0327 Tc 1.719 0 Td (treatment )Tj 0.251 0.251 0.247 rg 0.05 Tc 8.9033 0 0 8.1 400.24 705.36 Tm (of )Tj 0.0045 Tc 8.1 0 0 8.1 410.29 705.36 Tm (severe )Tj 0.0357 Tc 2.904 0 Td (steroid-dependent )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0477 Tc 8.1 0 0 8.1 499.1227 705.36 Tm (asthma\255)Tj EMC ET BT /T1_0 1 Tf -0.0084 Tc 8.1 0 0 8.1 299.0203 696.7335 Tm (tics. )Tj /T1_1 1 Tf 0.0192 Tc 1.973 0 Td (Allergy, )Tj /T1_0 1 Tf -0.0261 Tc 3.743 0 Td (1985, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0049 Tc 8.1 0 0 8.1 364.768 696.7335 Tm (40, )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 7.7353 0 0 8.1 378.13 696.73 Tm (58)Tj 0.435 0.435 0.431 rg 0 Tc 8.1 0 0 8.1 385.83 696.73 Tm (-)Tj 0.251 0.251 0.247 rg 0.0095 Tc 0.532 0 Td (64. )Tj -0.035 Tc 7.6511 0 0 8.1 298.95 687.61 Tm (9. )Tj 0.184 g 0.0188 Tc 8.1 0 0 8.1 313.4 687.61 Tm (Laursen )Tj 0.0135 Tc 4.03 0 Td (LC, )Tj 0.251 0.251 0.247 rg 0.05 Tc 8.3597 0 0 8.1 363.77 687.61 Tm (Taudorf )Tj 0.184 g -0.0175 Tc 8.1 0 0 8.1 397.88 687.61 Tm (E, )Tj 0.0198 Tc 1.483 0 Td (Weeke )Tj 0 Tc 3.495 0 Td (B)Tj 0.329 0.329 0.326 rg 0.636 0 Td (. )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 8.1 0 0 8.1 451.1132 687.61 Tm (-)Tj EMC ET BT 0.184 g /T1_0 1 Tf 8.1 0 0 8.1 460.7603 687.61 Tm (H)Tj 0.329 0.329 0.326 rg 0.027 Tc 0.767 0 Td (igh-dose )Tj 0.251 0.251 0.247 rg 0.0263 Tc 4.267 0 Td (inhaled )Tj 0.022 Tc -24.998 -1.067 Td (budesonide )Tj 0.0095 Tc 4.968 0 Td (in )Tj 0.0327 Tc 1.132 0 Td (treatment )Tj 0.05 Tc 8.9033 0 0 8.1 383.43 678.97 Tm (of )Tj 0.0163 Tc 8.1 0 0 8.1 392.05 678.97 Tm (severe )Tj 0.0283 Tc 2.844 0 Td (steroid-dependent )Tj 0.0319 Tc 7.885 0 Td (asthma. )Tj /T1_1 1 Tf 0.0144 Tc 3.632 0 Td (Eur )Tj 0.184 g /T1_2 1 Tf 0 Tc 8 0 0 8 522.65 678.97 Tm (J )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_1 1 Tf 0.0123 Tc 8.1 0 0 8.1 298.62 669.85 Tm (Respir )Tj EMC ET BT 0.184 g /T1_1 1 Tf 0.05 Tc 8.2081 0 0 8.1 323.12 669.85 Tm (Di)Tj 0.329 0.329 0.326 rg -0.035 Tc 8.0114 0 0 8.1 331.23 669.85 Tm (s, )Tj 0.251 0.251 0.247 rg /T1_0 1 Tf -0.0113 Tc 8.1 0 0 8.1 339.56 669.85 Tm (1986, )Tj -0.0201 Tc 2.511 0 Td (68, )Tj 0.0192 Tc 1.637 0 Td (19-28. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.035 Tc 7.5202 0 0 8.1 299.74 661.21 Tm (10)Tj 0.122 g 0 Tc 8.1 0 0 8.1 307.03 661.21 Tm (. )Tj EMC /Suspect <>BDC 0.251 0.251 0.247 rg 0.0281 Tc 1.188 0 Td (Spitzer )Tj EMC /Suspect <>BDC 0.0236 Tc 3.2 0 Td (SA, )Tj EMC ET BT /T1_0 1 Tf 0.0325 Tc 8.1 0 0 8.1 357.5659 661.21 Tm (Kaufman )Tj 0.184 g 0 Tc 4.267 0 Td (H)Tj 0.329 0.329 0.326 rg 0.819 0 Td (, )Tj 0.251 0.251 0.247 rg 0.0267 Tc 0.485 0 Td (Koplovitz )Tj 0.0412 Tc 4.448 0 Td (A, )Tj 0.0281 Tc 1.296 0 Td (Topilsky )Tj 0.184 g 0.05 Tc 8.1464 0 0 8.1 481.88 661.21 Tm (M, )Tj 0.0178 Tc 8.1 0 0 8.1 494.36 661.21 Tm (Blum )Tj 0 Tc 2.486 0 Td (I)Tj 0.329 0.329 0.326 rg 0.46 0 Td [(. )16(-)]TJ 0.251 0.251 0.247 rg 0.0181 Tc -27.065 -1.126 Td (Beclomethasone )Tj 0.032 Tc 7.225 0 Td (dipropionate )Tj 0.05 Tc 8.4599 0 0 8.1 404.55 652.09 Tm (and )Tj 0.0373 Tc 8.1 0 0 8.1 420.88 652.09 Tm (chronic )Tj 0.0418 Tc 3.615 0 Td (asthma. )Tj 0.05 Tc 8.2125 0 0 8.1 480.89 652.09 Tm (The )Tj -0.0001 Tc 8.1 0 0 8.1 497.67 652.09 Tm (effect )Tj 0.05 Tc 8.9033 0 0 8.1 519.76 652.09 Tm (of )Tj 0.0131 Tc 8.1 0 0 8.1 298.97 643.44 Tm (long-term )Tj 0.0247 Tc 4.502 0 Td (aerosol )Tj 0.0311 Tc 3.496 0 Td (administration )Tj 0.05 Tc 8.3916 0 0 8.1 417.52 643.44 Tm (on )Tj 0.043 Tc 8.1 0 0 8.1 430.06 643.44 Tm (the )Tj 0.0296 Tc 1.779 0 Td (hypothalamic-pituitary\255)Tj 0.0355 Tc -18.023 -1.125 Td (adrenal )Tj 0.0007 Tc 3.378 0 Td (axis )Tj 0.0344 Tc 1.896 0 Td (after )Tj 0.0309 Tc 2.13 0 Td (substitution )Tj 0.184 g 0.0296 Tc 5.277 0 Td (for )Tj 0.251 0.251 0.247 rg 0.0422 Tc 1.483 0 Td (oral )Tj 0.0245 Tc 1.963 0 Td (therapy )Tj 0.184 g 0.0416 Tc 3.438 0 Td (with )Tj 0.251 0.251 0.247 rg 0.0232 Tc 2.065 0 Td (corticosteroids. )Tj /T1_1 1 Tf -0.0054 Tc -21.58 -1.068 Td (Chest, )Tj /T1_0 1 Tf -0.0113 Tc 2.948 0 Td (1976, )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0201 Tc 8.1 0 0 8.1 343.1146 625.6767 Tm (70, )Tj EMC ET BT /T1_0 1 Tf -0.035 Tc 7.7578 0 0 8.1 356.07 625.68 Tm (38)Tj 0.435 0.435 0.431 rg 0 Tc 8.1 0 0 8.1 363.75 625.68 Tm (-)Tj 0.251 0.251 0.247 rg 0.0049 Tc 0.541 0 Td (42. )Tj 0.05 Tc 8.2134 0 0 8.1 299.46 616.56 Tm (II)Tj 0.435 0.435 0.431 rg 0 Tc 8.1 0 0 8.1 306.55 616.56 Tm (. )Tj 0.251 0.251 0.247 rg 0.0118 Tc 1.26 0 Td (Pedersen )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0011 Tc 8.1 0 0 8.1 348.8077 616.56 Tm (S, )Tj EMC ET BT /T1_0 1 Tf -0.0038 Tc 8.1 0 0 8.1 357.9283 616.56 Tm (Steffensen )Tj 0.05 Tc 8.5804 0 0 8.1 393.99 616.56 Tm (G, )Tj 0.0365 Tc 8.1 0 0 8.1 405.08 616.56 Tm (Ekman )Tj 0.122 g 0 Tc 3.316 0 Td (I)Tj 0.251 0.251 0.247 rg 0.401 0 Td (. )Tj /T1_1 1 Tf 0.05 Tc 8.2481 0 0 8.1 439.13 616.56 Tm (et )Tj -0.0054 Tc 8.1 0 0 8.1 447.79 616.56 Tm (al. )Tj 0.435 0.435 0.431 rg /T1_0 1 Tf 0 Tc 1.299 0 Td (-)Tj 0.251 0.251 0.247 rg 0.0294 Tc 0.895 0 Td (Pharmacokinetics )Tj 0.05 Tc 8.9033 0 0 8.1 298.48 607.44 Tm (of )Tj 0.022 Tc 8.1 0 0 8.1 307.69 607.44 Tm (budesonide )Tj 0.0095 Tc 4.968 0 Td (in )Tj 0.0178 Tc 1.006 0 Td (children )Tj 0.0021 Tc 3.683 0 Td (with )Tj 0.0319 Tc 2.065 0 Td (asthma. )Tj /T1_1 1 Tf 0.044 Tc 3.514 0 Td (Eur )Tj /T1_2 1 Tf 0 Tc 7.7 0 0 7.7 445.37 607.44 Tm (J )Tj /T1_1 1 Tf -0.0171 Tc 8.1 0 0 8.1 452 607.44 Tm (Clin )Tj 0.0044 Tc 1.983 0 Td (Pharmacol, )Tj 0.122 g /T1_0 1 Tf 0 Tc 5.054 0 Td (1)Tj 0.251 0.251 0.247 rg 0.0176 Tc 0.379 0 Td (987, )Tj -0.014 Tc -26.37 -1.067 Td (31, )Tj 0.0179 Tc 1.598 0 Td (579-582. )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 8.9863 0 0 8.1 298.52 584.41 Tm (REs)Tj 0.122 g 8.498 0 0 8.1 314.39 584.41 Tm (UME)Tj 0.329 0.329 0.326 rg 0 Tc 8.1 0 0 8.1 334.36 584.41 Tm (: )Tj EMC ET BT 0.251 0.251 0.247 rg /T1_0 1 Tf -0.035 Tc 7.2407 0 0 8.1 338.8 584.41 Tm (31 )Tj 0.036 Tc 8.1 0 0 8.1 348.87 584.41 Tm (enfants )Tj 0.0279 Tc 3.438 0 Td (asthmatiques )Tj 0.05 Tc 8.4919 0 0 8.1 423.76 584.41 Tm (ont )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 8.1078 0 0 8.1 437.67 584.41 Tm (ete )Tj EMC ET BT /T1_0 1 Tf 0.0383 Tc 8.1 0 0 8.1 450.22 584.41 Tm (traites )Tj 0.05 Tc 8.2928 0 0 8.1 474.25 584.41 Tm (pa)Tj 0.122 g 0 Tc 8.1 0 0 8.1 482.87 584.41 Tm (r )Tj 0.251 0.251 0.247 rg 0.0367 Tc 0.704 0 Td (inhala)Tj 0.122 g 0.0409 Tc 2.614 0 Td (ti)Tj 0.251 0.251 0.247 rg 0.05 Tc 8.1711 0 0 8.1 514.48 584.41 Tm (ons )Tj 8.2927 0 0 8.1 298 575.29 Tm (de )Tj 0.0208 Tc 8.1 0 0 8.1 312.49 575.29 Tm (beclomethasone )Tj 0.05 Tc 8.3173 0 0 8.1 372.39 575.29 Tm (et )Tj 8.2927 0 0 8.1 384.4 575.29 Tm (de )Tj 0.022 Tc 8.1 0 0 8.1 398.89 575.29 Tm (budesonide )Tj 0.05 Tc 8.3101 0 0 8.1 443.44 575.29 Tm (au )Tj 0.0415 Tc 8.1 0 0 8.1 457.84 575.29 Tm (cours )Tj 0.184 g 0.05 Tc 8.2974 0 0 8.1 482.8 575.29 Tm (d'une )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.042 Tc 8.1 0 0 8.1 507.75 575.29 Tm (etude )Tj EMC /Suspect <>BDC 0.0217 Tc -25.827 -1.067 Td (randomisee )Tj EMC ET BT /T1_0 1 Tf 0.0064 Tc 8.1 0 0 8.1 343.6035 566.6473 Tm (avec )Tj 0.0338 Tc 2.619 0 Td (permutation )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0061 Tc 8.1 0 0 8.1 412.7289 566.6473 Tm (croisee )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.2998 0 0 8.1 442 566.65 Tm (du)Tj 0.122 g 0 Tc 8.1 0 0 8.1 451.19 566.65 Tm (r)Tj 0.251 0.251 0.247 rg 0.05 Tc 8.4343 0 0 8.1 453.99 566.65 Tm (ant )Tj 0 Tc 8.1 0 0 8.1 471.79 566.65 Tm (2 )Tj 0.184 g 0.714 0 Td (x )Tj 0.251 0.251 0.247 rg 0.762 0 Td (6 )Tj 0.0355 Tc 1.243 0 Td (sema)Tj 0.122 g 0 Tc 2.138 0 Td (i)Tj 0.251 0.251 0.247 rg -0.0127 Tc 0.304 0 Td (nes. )Tj 0.023 Tc -26.552 -1.126 Td (L'excret)Tj 0.122 g 0 Tc 3.433 0 Td (i)Tj 0.251 0.251 0.247 rg 0.05 Tc 8.3916 0 0 8.1 328.24 557.53 Tm (on )Tj 8.2927 0 0 8.1 339.28 557.53 Tm (de )Tj 0.0235 Tc 8.1 0 0 8.1 349.84 557.53 Tm (cortisol )Tj 0.0204 Tc 3.498 0 Td (libre )Tj 0.184 g 0.0442 Tc 2.191 0 Td (dans )Tj 0.0269 Tc 2.311 0 Td (deux )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0264 Tc 8.1 0 0 8.1 433.351 557.53 Tm (echantillons )Tj EMC ET BT /T1_0 1 Tf 0.0378 Tc 8.1 0 0 8.1 477.5203 557.53 Tm (d'urines )Tj 0.05 Tc 8.2927 0 0 8.1 507.76 557.53 Tm (de )Tj 0.0263 Tc 8.1 0 0 8.1 518.35 557.53 Tm (24 )Tj 0.0243 Tc -27.136 -1.126 Td (h, )Tj 0.003 Tc 1.177 0 Td (collectes )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 13.4 0 0 13.4 340.18 548.41 Tm (a )Tj EMC /Suspect <>BDC -0.035 Tc 7.9307 0 0 8.1 347.95 548.41 Tm (Ia )Tj EMC ET BT /T1_0 1 Tf 7.704 0 0 8.7 357.52 548.41 Tm (fin )Tj 0.184 g 0.05 Tc 8.2927 0 0 8.1 369.04 548.41 Tm (de )Tj 0.251 0.251 0.247 rg 0.0427 Tc 8.1 0 0 8.1 380.56 548.41 Tm (chaque )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0256 Tc 8.1 0 0 8.1 408.4888 548.41 Tm (periode )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.2927 0 0 8.1 437.2 548.41 Tm (de )Tj 0.184 g 0.0268 Tc 8.1 0 0 8.1 449.26 548.41 Tm (traitement, )Tj 0.251 0.251 0.247 rg 0.0352 Tc 5.026 0 Td (s'es)Tj 0.122 g 0 Tc 1.552 0 Td (t )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0252 Tc 8.1 0 0 8.1 508.2442 548.41 Tm (avere )Tj EMC ET BT /T1_0 1 Tf 0.0127 Tc 8.1 0 0 8.1 297.9763 539.7592 Tm (significativement )Tj 0.0205 Tc (plus )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0081 Tc 8.1 0 0 8.1 374.7967 539.7592 Tm (elevee )Tj EMC ET BT /T1_0 1 Tf 0.0183 Tc 8.1 0 0 8.1 397.8331 539.7592 Tm (\(moye)Tj 0.122 g 0 Tc 2.617 0 Td (n)Tj 0.251 0.251 0.247 rg 0.0084 Tc 0.533 0 Td (ne )Tj 0.184 g /T1_3 1 Tf 0 Tc 7 0 0 7 432.37 539.76 Tm (= )Tj 0.251 0.251 0.247 rg /T1_0 1 Tf -0.0023 Tc 8.1 0 0 8.1 439.11 539.76 Tm (76.3 )Tj 0.0263 Tc 2.143 0 Td (nmolfjour\) )Tj 0.0162 Tc 4.969 0 Td (au )Tj 0.05 Tc 8.1879 0 0 8.1 507.28 539.76 Tm (cours )Tj 0.184 g 8.7609 0 0 8.1 298 530.65 Tm (du )Tj 0.251 0.251 0.247 rg 0.0313 Tc 8.1 0 0 8.1 311.98 530.65 Tm (traitement )Tj 0.05 Tc 8.3101 0 0 8.1 351.76 530.65 Tm (au )Tj 0.0185 Tc 8.1 0 0 8.1 365.29 530.65 Tm (budesonide, )Tj 0.05 Tc 8.142 0 0 8.1 410.32 530.65 Tm (que )Tj 0.0472 Tc 8.1 0 0 8.1 427.69 530.65 Tm (pendant )Tj 0.0064 Tc 4.079 0 Td (le )Tj 0.184 g 0.0313 Tc 1.31 0 Td (traitement )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0 Tc 12.8 0 0 12.8 511.07 530.65 Tm (a )Tj EMC /Suspect <>BDC 0.184 g -0.035 Tc 7.9307 0 0 8.1 520.27 530.65 Tm (Ia )Tj EMC ET BT 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0208 Tc 8.1 0 0 8.1 298.57 522 Tm (beclomethasone )Tj 0.0473 Tc 7.099 0 Td (\(moyenne= )Tj 0.0009 Tc 5.094 0 Td (53.7 )Tj 0.0263 Tc 2.146 0 Td (nmolfjour\) )Tj 0.05 Tc 8.3324 0 0 8.2 454.94 522 Tm (\(p )Tj /T1_3 1 Tf 0 Tc 9.1 0 0 9.1 463.54 522 Tm (< )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0001 Tc 8.1 0 0 8.1 470.32 522 Tm (0.01\). )Tj EMC ET BT /T1_3 1 Tf 0.0007 Tc 8 0 0 8 493.27 522 Tm (La )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0009 Tc 8.1 0 0 8.1 505.36 522 Tm (differ\255)Tj EMC ET BT /T1_0 1 Tf 0.0093 Tc 8.1 0 0 8.1 297.9919 512.8875 Tm (ence )Tj 0.0393 Tc 2.133 0 Td (entre )Tj -0.0135 Tc 2.432 0 Td (les )Tj 0.184 g 0.0269 Tc 1.302 0 Td (deux )Tj 0.0187 Tc 2.319 0 Td (medicaments )Tj 0.0313 Tc 5.737 0 Td (s'est )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0145 Tc 8.1 0 0 8.1 427.6 512.8875 Tm (averee )Tj EMC ET BT 0.122 g /T1_0 1 Tf 0.0024 Tc 8.1 0 0 8.1 451.6894 512.8875 Tm (pl)Tj 0.251 0.251 0.247 rg 0.05 Tc 8.1842 0 0 8.1 458.4 512.89 Tm (us )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.048 Tc 8.1 0 0 8.1 468.46 512.89 Tm (marq)Tj 0.122 g 0 Tc 2.254 0 Td (u)Tj 0.251 0.251 0.247 rg 0.0226 Tc 0.463 0 Td (ee )Tj EMC ET BT /T1_0 1 Tf 0.0291 Tc 8.1 0 0 8.1 500.0743 512.89 Tm (chez )Tj 0.184 g -0.0135 Tc 2.135 0 Td (les )Tj 0.251 0.251 0.247 rg 0 Tc -27.09 -1.127 Td (8 )Tj 0.036 Tc 0.777 0 Td (enfants )Tj 0.0185 Tc 3.379 0 Td (qui )Tj 0.05 Tc 8.138 0 0 8.1 345.04 503.76 Tm (ont )Tj ET BT /Suspect <>BDC /C0_0 1 Tf 0 Tc 4.64 0 0 6.72 358.57 503.76 Tm <0072007E00750020>Tj EMC /Suspect <>BDC /T1_0 1 Tf -0.0305 Tc 8.1 0 0 8.1 376.04 503.76 Tm (1000 )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.3173 0 0 8.1 393.03 503.76 Tm (et )Tj ET BT /Suspect <>BDC /T1_0 1 Tf -0.0108 Tc 8.1 0 0 8.1 402.44 503.76 Tm (1200 )Tj EMC /Suspect <>BDC 0.184 g -0.0329 Tc 2.22 0 Td (IJ.g/jour )Tj EMC ET BT 0.251 0.251 0.247 rg /T1_0 1 Tf 0.05 Tc 8.142 0 0 8.1 447.76 503.76 Tm (que )Tj 0.0094 Tc 8.1 0 0 8.1 462.64 503.76 Tm (chez )Tj 0.184 g -0.0135 Tc 2.135 0 Td (les )Tj 0.251 0.251 0.247 rg -0.033 Tc 1.365 0 Td (22 )Tj 0.0428 Tc 1.239 0 Td (enfan)Tj 0.122 g 0 Tc 2.438 0 Td (t)Tj 0.251 0.251 0.247 rg 0.285 0 Td (s )Tj 0.0185 Tc -27.789 -1.067 Td (qui )Tj 0.05 Tc 8.4919 0 0 8.1 311.92 495.12 Tm (ont )Tj ET BT /Suspect <>BDC /C0_0 1 Tf 0 Tc 4.8 0 0 6.24 326.4 495.12 Tm <0072007E00750020>Tj EMC /Suspect <>BDC /T1_0 1 Tf 0.0083 Tc 8.1 0 0 8.1 343.54 495.12 Tm (800 )Tj EMC /Suspect <>BDC -0.0306 Tc 1.847 0 Td (IJ.g/jour. )Tj EMC ET BT 0.184 g /T1_0 1 Tf 0.05 Tc 8.1466 0 0 8.1 388.72 495.12 Tm (Quatre )Tj 0.251 0.251 0.247 rg 0.036 Tc 8.1 0 0 8.1 415.11 495.12 Tm (enfants )Tj 0.05 Tc 8.4919 0 0 8.1 442.96 495.12 Tm (ont )Tj 0.0249 Tc 8.1 0 0 8.1 457.83 495.12 Tm (eu )Tj 0.0195 Tc 1.374 0 Td [(une )-54(excretion )]TJ 0.0141 Tc 6.094 0 Td (de )Tj 0.0235 Tc -27.2 -1.126 Td (cortisol )Tj 0.184 g 0.0116 Tc 3.438 0 Td (inferieure )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0 Tc 12.4 0 0 12.4 360.35 486 Tm (a )Tj EMC ET BT 0.184 g /T1_0 1 Tf -0.035 Tc 7.9307 0 0 8.1 366.67 486 Tm (Ia )Tj 0.251 0.251 0.247 rg 0.0115 Tc 8.1 0 0 8.1 374.81 486 Tm (limite )Tj 0.0378 Tc 2.615 0 Td (normale )Tj 0.05 Tc 8.3101 0 0 8.1 426.16 486 Tm (au )Tj 0.0415 Tc 8.1 0 0 8.1 436.72 486 Tm (cours )Tj 0.05 Tc 8.7609 0 0 8.1 457.36 486 Tm (du )Tj 0.0313 Tc 8.1 0 0 8.1 468.94 486 Tm (traitement )Tj 0.05 Tc 8.4273 0 0 8.1 506.41 486 Tm (par )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0091 Tc 8.1 0 0 8.1 519.78 486 Tm (Ia )Tj EMC ET BT /T1_0 1 Tf 0.0208 Tc 8.1 0 0 8.1 298.0911 477.3735 Tm (beclomethasone)Tj 0.122 g 0 Tc 6.733 0 Td (. )Tj 0.251 0.251 0.247 rg 0.0099 Tc 0.663 0 Td (Ceci )Tj 0 Tc 2.311 0 Td (a )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.05 Tc 8.1078 0 0 8.1 383.91 477.37 Tm (ete )Tj EMC ET BT /T1_0 1 Tf 0.0187 Tc 8.1 0 0 8.1 397.36 477.37 Tm (observe )Tj 0.0094 Tc 3.615 0 Td (chez )Tj 0.05 Tc 8.2333 0 0 8.1 445.44 477.37 Tm (un )Tj 0.0499 Tc 8.1 0 0 8.1 457.35 477.37 Tm (enfant )Tj 0.05 Tc 8.3101 0 0 8.1 483.28 477.37 Tm (au )Tj 8.1879 0 0 8.1 494.8 477.37 Tm (cours )Tj 0.184 g 8.7609 0 0 8.1 516.88 477.37 Tm (du )Tj 0.0313 Tc 8.1 0 0 8.1 298.06 468.25 Tm (traitement )Tj 0.251 0.251 0.247 rg 0.05 Tc 8.7989 0 0 8.1 334.95 468.25 Tm (au )Tj 0.0185 Tc 8.1 0 0 8.1 345.61 468.25 Tm (budesonide. )Tj 0.184 g -0.035 Tc 8.1134 0 0 8.6 388.76 468.25 Tm (Le )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0289 Tc 8.1 0 0 8.1 398.87 468.25 Tm (resultat )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.2644 0 0 8.1 426.71 468.25 Tm (n'a )Tj 0.184 g 0.02 Tc 8.1 0 0 8.1 439.21 468.25 Tm (pas )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.021 Tc 8.1 0 0 8.1 452.5507 468.25 Tm (ete )Tj EMC /Suspect <>BDC 0.184 g 0.0042 Tc 1.484 0 Td (influence )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.4273 0 0 8.1 496.81 468.25 Tm (par )Tj ET BT /Suspect <>BDC 0.251 0.251 0.247 rg /T1_0 1 Tf 0.0309 Tc 8.1 0 0 8.1 509.97 468.25 Tm (!'age )Tj EMC ET BT /T1_0 1 Tf 0.05 Tc 8.2927 0 0 8.1 297.52 459.61 Tm (de )Tj 0.184 g 0 Tc 8.1 0 0 8.1 312.21 459.61 Tm (!)Tj 0.329 0.329 0.326 rg 0.0136 Tc 0.319 0 Td ('en)Tj 0.184 g 0.0037 Tc 1.244 0 Td (fant. )Tj 0.251 0.251 0.247 rg 0.05 Tc 8.3613 0 0 8.1 346.99 459.61 Tm (La )Tj 0.0062 Tc 8.1 0 0 8.1 362.29 459.61 Tm (sign)Tj 0.122 g 0 Tc 1.723 0 Td (i)Tj 0.251 0.251 0.247 rg 0.0018 Tc 0.294 0 Td (fication )Tj 0.0174 Tc 3.912 0 Td (clinique )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0 Tc 12.8 0 0 12.8 443.39 459.61 Tm (a )Tj EMC ET BT /T1_0 1 Tf 0.0448 Tc 8.1 0 0 8.1 454.01 459.61 Tm (long )Tj 0.0249 Tc 2.732 0 Td (terme )Tj 0.0141 Tc 3.133 0 Td (de )Tj -0.0053 Tc 1.778 0 Td (ces )Tj 0.0221 Tc -26.904 -1.126 Td (observations )Tj 0.05 Tc 8.2124 0 0 8.1 343.6 450.49 Tm (doit )Tj 0.0286 Tc 8.1 0 0 8.1 359.91 450.49 Tm (encore )Tj ET BT /Suspect <>BDC /T1_0 1 Tf 0.0413 Tc 8.1 0 0 8.1 384.8661 450.49 Tm (etre )Tj EMC /Suspect <>BDC -0.0001 Tc 1.896 0 Td (elucidee. )Tj EMC ET endstream endobj 12 0 obj <>stream Hd͊zy8 >sRhF^#y QG#Oç==o/ϧ;c_mӷKv|~_oo~y>}~W=|z>{O݇q~?>Ï?o+~ߒ~;%zΏx߽w;>lp?(O?{wٸ^ PZUuTGu^5P5FjFDMԤU PjVjUmFmک]uPuNNE]E5|| _#_k55|| _#_k55|| _#_k55|| _#_k5Z||-_+_kZ||-_+_kZ||-_+_kZ||-_+_ku:||_'_uu:||_'_uu:||_'_uu:||_'_uz||=_/_z||=_/_z||=_/_z||=_/_ || ߀o77 || ߀o77 || ߀o77 || ߀o77 KG#(~? ?G#(~? ?G#(~? ?G#(~? ?z $߄o77MM&|| $߄o77MM&|| $߄o77MM&|| $߄o77MM&||3,ߌo77f||3,ߌo77f||3,ߌo77f||3,ߌo77f|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--|| "߂oȷ[--||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V||+*ߊoŷʷ[V|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|| &߆o÷ɷmm6|ۯ\t;]~~߅ww;]~~߅ww;]~~߅ww;]~~߅w߁w;;|C߁w;;|C߁w;;|C߁w;;|C߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S߉w;;NN|'S ߅w]..|K ߅w]..|K ߅w]..|K ߅w]..|?|x>/Filter/JBIG2Decode/Height 1752/ImageMask true/Length 17961/Name/X/Subtype/Image/Type/XObject/Width 1240>>stream +(O]KS XwkPc$kR^ Ȫrr ;,a;fO'5J#HQmmuh|-{|*nHƻ[܌HwɁT^އ]i1D"ɓk0;L(Ӓܼ>3]n~:l\EE6K$h S{0ő\( 2 8vWť7])''Lv0-j7~d: 5%why$mdܱϪJS!@՝q^؉ 0P.,3cvleM3PN/ST=Q0eHC]~X#;Kv&~q1C^[W' ܤ:VVisRߑ8KX ,򭪑ZU$w(Ҍ +/V/92?EFoio? 翃f%>fLh%?K,A`ȵPYAx fۣE1N+ȦBfj8z(> 1Wڞ 2w9Q}:b*_#R}򩉗RVǹ?)v&3?a%RF ]F4|uXྖZdN7 =rۗ/:w*!0hhSrt_YBq桴(Beh-u v#t<%ħIJs~iCC^4ExALToOv$ xyyd c.Q"{fo;7*zDyeraR(Ij4R"l gzW#JxE»?87ɿF].1ɱ5.7tx z<.LAipKWB+I^+ &Uۮ1|ʚ[dw ȷ(,}lFA4N8b%V$ tT"ȧPIHu˓͡9!ǞQW`%/xpSvR;7aBC! v.gI6;hή E9H9Q8?[kKQZm3E18fu۟^ goZZ=a]]MhdhvvYNXBd?`(OB2({-)QkFY ![HFUI2;]3?F`L/w|f xB?eY1|HNӑRWDh u;sVh;  Ϫ]'P0[R Z'ݓ?^|yv goğ-b0,\+'*N(1wWDR/ZQU8Jcxo9WcO'bS JbWtQҬvTHR:VrJ< Yܸc5WᨢhE%<6Xi  H??<`4ȑO@J䧅: шR8n! HrDn?mQBln`oD}P%R>QZ[oϧ&J$ RLdw>`%D+ڇ^#\"8e֥4_fy{K?еdC`Fӛu{wǯaOT6 jP{6fI*7JcP bٸmG?aHZrխKWpx֜s,`wOӼnC  !LBv8sۣYH8O"Z;)YP6W.3dPHt*i-RjLg^, ft,'ˬ]8IA=b?jɤ'/k:)T c{2y8xE"H1p#O k0Z ZH ¸ V/> P^Pޜd~ǫ-guM#fW^Ts ]#ɵ1-~T45Uh@3my2@6tʗ[h 9k1>ACAWEF-+.>+5)ANnC& \ۘ'Shm}ءf3?ɯmt_aKEnI׌:dj4y^l@b4&J1ۋ[#qhYwAm#8>Cl<*ZJb uv3QCY]PP|-#Z9>fX`Tegڔ!etTOSFЛPN.ʹ*~g,/@ܲz0Vwz ʅרSOG޽'UswO؏"[ئs%-i?nF "ذ4F]N1'j ؠ;PKn.XWdkp0` n &]ݼ; &>P~Ps9bB!{ɜ1ƋhD)wHDCpUGU"yALt[(IT3׌Y~s/cUe-%aDtuuSXZʧu)ޔV^a]<@:)g5`ɫc#M[e n:Wa~6rq]UXZ9%Vm&N ,d䑾ʷޒm0\CݯEk3W5#vnpJοJ@o@~q Z*GPs6_z iJ0rf|3:W/Du:I=6ޕG4OQ no^Ubn Z?y `,XeuW1 m'J$Lqɳw!YF>b5=BԈ46E+[;g g@,f~(y&-0J IYhvHڳ,n76TvNA뿅 :8@+`qiR;Po4)nP[ds, HIψytj aNu>A6^0MY|ȗDKǾBvRxl+,]y"-zThmÀi#w#8E[ 6Y S"XC#vu'uD0~ q-"K_MoEXMtG2{Ykf0*!I,_A[k zK6aO%94bЍy; rUd6&ELTo3R|- @h>J.&N}c8;tհD ;9}!PqI xuh-#-6Nc͕z1;0j\00CL H"oy!@$JfCPUm9XIOD~cCH x$-"*DzOd:xY .\$K]xE|^ fs8 urJq<#ȻOeg"q)_^ɛ%5]7?Wߗ%>ff% Aw \F^c|Prz`|[r9op: ¯ݪgg%kҦP̖ ᠏C.V̉V[y੥غKT>I^VH%uH}3]X1 g|RD롩&Efv1G?PqD]u=䝢/E<wFG?M"q#ldH\@yT~.`{?$Bz[.1k^ 2UrăGDp6 <" L"~YGƫa9=2T)jŖ"gh]30y>d?U74+L:TC`m˅/ħ7`mjJ@Xvah5/@fΕ^K+butc좆v.~Ljs1G;HI?v}=: !W՘ >[mqUlҷ9D5|@m H\ZzqNh-<~r>Ol!y}.trG,o!Dl]~uJ4Du[ZHhHh¥ֶ!2ٺuspq09e5&OhX'AVI!g3s"upX>qŶ^(G jxs e~50)}ͳ1g _yf/oЪwV+(,U_E:a2$ѿԡ/^"^Z} 67 6g_|Գ 51x_| Z?r68.Wq."G灘<э61#~l,*᡿CP>_J^17^Daf3k@ `w`0$mM 2Lg݈'oz=]I V(p~N| !a Ȏɑgy\ܜl[=Cﮋ'YQB}p4B %ѠK~QIhM~&ZG̅h9뀾;+ X#1>0s9b%d9 /7LslN?!itţ6}Kt{U~~ƔiDFq*/.S(µw@bRQ*Azyn('(M$Km̓-}̾`},ʗ뜢ԩ*9{cxQ`$y(czو&v\h0jß}dL9B(q{Vm;M *`UP iڅ%#DfK}%=wʧ&9v]0 {'c ǧ{(b*.bԲ"EGc$G,Ӷ{I̍ x da|S9꘨x+D1oeh6 ˰ ڻ1#:vj0N`l9F&p$D}f*\T'm%wAºŞ\'ǰ.\0ʯ#`CIt%HGB1 bXT<[;n{QZI$d Wdzګ; f23~9?'-`WQW!娏wNU?o1b'Zas1VnW:M|kO,   v! ͪ,,,LYФ+?%hEA2[$6:t9 ( SA5}'bƆk ;7-n=ZE}kTg@6 $X&oʷ2z>x\TܘyZw] knGӁ!< \UqiX{ivE\l=N6##!1wQyXm(tO/:yj5Nx7A]D}+gtǟݥհ v\ULYkPT։ [ڧ8ޒ=p+.NG8[{(woXi!ze$AdFrg*Yg]Z?xJJZ$mxw}6(+rnz"[A}o|`:WMj2ayl#aPSWƤR'E3ٓWu2۽=!smgą-~ e#ՐTQ~j^B4 TZ`7+"y OnogC$k#S븍_#ehYq$ .NBN+=^xt8aU8^|tjJE( D &'lT~ Axv3O)K'PGn<yenELZ"o{ea䥑埝ʙ?.?咨*l2?6D5 97a]-h#nD9G-E-hZmD9|iN0|A&Ofq5q8Ҏ1[튳lTd3>ސURf3RVǨqgV[z,kKȆubuB[di 17R9ĝBsGkHu"SzwSh7KO)O>KW:7i,7&#{K׭@zעO fᣪ F$&% 7i׿r[?#k7#bJ!y]phyԫµ~〖Z錄me8#hPds/ {42 @!{TbqpCRrImF(K!NY^B 55zk)dS2abIGㆣkS/}j_\-ɑiY7_c$2 OG.MCJ8ipjoWPz#܋%f,@M{w qQwx=t͗!czHEM+tcT $a8['5C(Քɑg0"!`ݲ(2)ݚ?7:vZW/ތD# %4KWĶVQ=5"x kRz##t@C@75M'4:Q7-RyƦ{`nX{'7%eVz,iJPJ4R.W{.<+^?=#I):>|((/mƥkNE<D1qMf{ 4lBZ1h/vRq/C٨P 5W~[t\iBm/g#k#0!K7̴%+VV2kq (qru dx[p&(4W92瘩6JS1cQ1.),{k/:9غB's "Ia얩l華a> q)a[`C \QaQ%S{šCKy֘7a-SlYgDCRgl[IFޟ&N߆cqf;߻d>&QΚH+%sDj D!{ ')".i͜͵[Q _hpr5d<`s?Jj `}tW0UoXC: Bu9s3y\cHPPT~Y*c/8*8xAjKYZO7ReVOEmC9!) jk&ؓO\H-Fo[S0 %c' ]vx;*863je>C%Zpg.AMy-P.p!u4˂C>WѶ\E9J.dt T54DMi@e.]fL֥ GtEρBv9-3vWJy(POh2~2ijĚ w^t԰@Q&؎ 2xD*TG?=6>b #Jqx.>OPɸx's ބka6(Fb h]1f^\_)RDA$Fi/>G=6Vԡv眐CEµ-kЅmM3Nߡn"+ʰ<@?p0{/ g-Whn69qoCiäYc(Ąe竕2= 0x=^pyj{G>G7c -F[-*2`퍇Tu] 챞=AYi4jJH7WN(5̔sU501^Dw[3o^(Җ6ވm`gcMn81/t·'^mfFU H9=lh_D\-H#6 ),T9- H|}UL$Т򙐇R{j\ڂX$+癌IBB:ѢXYvD2tܽ~+K*[z~ؓ/X/7ؗ\9aGZɄT>cZB0҈?'lhtyЇ"D$;mr &2il?btSif>N0@ l "mU(YC ;7sm$೼k$91e@,.q/i|813^-t=P~϶9ܸ1}%9Pq7 ; T{F&fT9~MXGKrSqD z5 Dr`)RdVl0Rz;)&whT,N)róHzf B. ordEvDoE/IUl>]5>SS9g /X1O4IZʯXkmCl+}$z*&Fvw+NX_|Y1T :O׍V5G? E&8!D: Pdy!_Vd'Njpۉݻa41n%b,)I g'Q(Aе)[Zs7*2xO saM"I(4-He({qo3|[=TWЍ%@ƎǶ❌LTXN>՘*̈w&9[@P@ja'T`.1\bo,Ii_ksnw1)[TE':u+ >JV *CN \6?x52<"R$$|ǭ8˗`i͐x~:3c4,H U_vay: R#̵!ddxr]]Vj[Hk.܅M^x@We(0ϕ-)m+}$TŽE'|rjkd(WtE#}D0rZB78W1$_\na43p]y9Ӣl?Eru4nDry(ujg|M=4x{D+eLi@~ L]7בX%X/#rsTՙZOCK1 خ]MdJqS[{:7+b-Q58=\yYc> E f¤#pU"c}b+9V\ ܁L.e!1Sp&GnAy: ,<: @ ge7Ȱa.ͣfG'"æmfnbkp٦{07q1+vqV7zkuL z !y{oe M/bHODm/gbv Y [N}ᯂx>rù6*7cX>O k/ +438=Gq'FKh\J3):3rqTa ;G#=t*.פN(lD7`/jKCJg|֖S#C\ o-̛|&D&Kkxһ$y&5 vjU:DQ&AL*9+b 0cI=JY!u!] ڶZ%!&< xG0$`0Tb H5ג4.ݰwG8 '+cR[?-/t^Ep]pvU*֡vzPknVc8Ř"ם4epv9V#ƫ;!hǍsp7_Ef&S@}n("(zS4.*gbj_ncO뿔j kCƬ6Xs1mjB?&e v^KPi]22F +!g,I59 G0#) lE&-rg^^&tVc񇥫vsECnd+v0 wLΝ6FZ]a"jP8="K ,bκ_ዽWE%M58߼,*H|z >@\? ydT$)zA ٿoj> XJy.MSsY:ߪ*1W6WTJU ϵ|13{(ʺf4} l6AD~u~,\*M}u.hGmC}!07$B!d}3[,E!z3`Ӫ'';X Q;WP:Hu*(sa'M}V荲T }a*);é .v}FSofJgƞ3ne u30[F`W(kK8~YȐBww A '1ݥ Y (JMBC(ߣ[B1s f))}Ioc%YFI(tenKe$X#R!V86H%sU݈2!U`$CD7 urۃPRK^H+7jj~ TeYr=3OmB|lvz+ןiZ}"'B^PSFNLd[廍95˰ G--Mv96o33JCM/K!wL>0Nv؆0hxDg"(:~H"4ѿxdej[|>ZQr4>Kx6Yn/B*[(>` m~5\ފ堐CCr: '5uM WBЎOrA@X#jjӇ߂B!8 eJ~O8Jj  cc$c3(R |l-QWYywN6w6̟lN[֋OQ5ZPIh}=d.찘 @TP<(͉mrU+ %Fö [ OUF _o_X\؃j >ԁ֫ 1M};u1P bl2kM `5?Yv%bA\r Wq%wwKaBWJZJۑsɛ]9NOD젌JnE݈Fx8nʶo|avO!NJ8a> ç<w ?֦J:ZJ^WBXh  O+޵kbHs p9` C5!4_/J~aI1'Vbqz<i4Ŕi),?f$?u[/.i<&tmzVyqAڥȠk&V1E j_v4Yz^ 첹B^nd_5QcLO-@y9Fg%_s) $ϩ+HNk' D婓!BN:b5pd8eqh?/- ;*6)M5!1]B|U+.KSgDzm G:OI1x\2v٭:/d*z WP#炔w*8T쒡?R7%6"`AHHa{X jyNzjt>EG&Om4–6l m8i肄Ԡ/zL':5py; *ZKu ^(RHf&P2]_UQa 'Ufgг敖l63?&gbꥯ[bֈD*ةPs'UM VT˸ /}˛ge9K 7W' ve8HZ;ޕ}Ԣ?rѲjk;wCaH`̸4UT%8 i2NS8Ȝl˃i-<|HN)Rm-lOOPM_%-x٩o{DߖXdVV"hp(s=9h*+u~x@'+&Lf-!Ihb>[͇`vEhuW^J>H#_7o.e ~LQ4LG}ИrR(Rq;<@mTJ?AZ@]9l'ʥ%{1mit(Ol6$ ?<'D&7yI')~|r}>'=b̦(PSxI!W*?A2cP0f܋{KԬ5yah|XzBvOIDqWh1UzRS̲0[#= A|_1}XP5ƽ/\\:#˜f\ӛcq<2;LI1.9=;! >F!>e/uĶ5Ty}vA}P}d5`wZBuuKq⃟/pJHҦ>stream h22Q0P02U0U02S0W0475R0Q04210=w endstream endobj 15 0 obj <>stream h޼Sj0 @p|@)JT20&bRyAS6@:sSvF+ 8mZpok*maTg!U:a*ڸ .%>D~: =yp$u#sQ*6ۑx, r_7筺#te7R)|x$Evj/1Y(fF8o 4^1 endstream endobj 16 0 obj <>stream h26W0P0P07T0T4U ($敄$QER+JS+C* RKJA%vv@c]KsAvv5! endstream endobj 17 0 obj <>stream 2012-10-24T10:39:08+01:00 2012-09-17T11:46:04+01:00 2012-10-24T10:39:08+01:00 Canon iR-ADV C2020L PDF application/pdf uuid:15e9e1cc-4d0d-49ee-84d9-28ef8da6f90a uuid:7c29fe70-7b33-4a0f-8782-d2aa8d420bf3 Adobe Acrobat 10.14 Paper Capture Plug-in endstream endobj 18 0 obj <>stream h21P0Pw/+Q0L)61 )BHXʂTb;;t 6 endstream endobj 19 0 obj <>stream hḺ 0_-R{Z)6HArHAY!\ȱv>!UUU, ָ'X o]_A4Kf)pO|آ [.˫]S3ik. endstream endobj 20 0 obj <>/Filter/FlateDecode/ID[<0DC88616E7EFC848A53E432565F5C6CA><33D73130D12D3D42A986E5D8F7DEAAFF>]/Info 41 0 R/Length 115/Root 43 0 R/Size 42/Type/XRef/W[1 3 1]>>stream hbb&Fu$N#D- n[$;HW9"=@$CXL|u`i`@{%E$?tF I"L` (j endstream endobj startxref 116 %%EOF